Development and evaluation of urine based rapid molecular diagnostic test for pulmonary tuberculosis with potential for point of care: Cape Town Cohort by Patel, Krutarth
 
 
 
 
 
 
 
Out of the 
Department of Infectious Disease and Tropical Medicine  
Medical Centre of the  University of Munich (LMU),  
Development and Evaluation of Urine based Rapid Molecular 
Diagnostic Test for Pulmonary Tuberculosis with Potential for Point of 
Care: Cape Town Cohort  
Doctoral Thesis 
for the awarding of a Doctor of Philosophy (Ph.D.) 
at the Medical Faculty of 
Ludwig-Maximilians-Universität, Munich 
Submitted by 
Krutarth Patel,  
born in 
Surat, India.  
Submitted on 
28. April 2017  
2 
 
Supervisors LMU: Title, first name, last name  
Habilitated Supervisor Prof. Dr. Michael Hoelscher  
Direct Supervisor Dr. rer. nat. Christof Geldmacher, PD   
 
SupervisorExternal:   
Local Supervisor  Dr. Ines Labugger  
 
 
Reviewing Experts: 
1st Reviewer Prof. Dr. Michael Hoelscher 
2nd Reviewer Dr. rer. nat. Christof Geldmacher, PD  
 
Dean: Prof. Dr. med. dent. Reinhard Hickel 
 
Date of Oral Defense: 23. November 2017 
 
  
3 
 
ABSTRACT  
Background: Current sputum-based diagnostic tests for tuberculosis (TB) do not serve 
all target populations, making optimal diagnosis difficult. TB diagnosis among scarce 
sputum patients is challenging for timely diagnosis and treatment initiation. Thus, an 
alternative non-sputum-based diagnostic test is urgently needed. Mycobacterium tuber-
culosis (MTB)-specific transrenal (Tr) DNA from urine is a potential target for molecular 
testing to close this gap in TB diagnosis. The objective of this cross-sectional study was 
to evaluate the accuracy of a novel, molecular test using a portable fully-automatic 
analyser with the potential for usage in limited resource settings at the point of care. 
Materials/Methods: Spot urine, blood and sputum samples from 428 adults with sus-
pected pulmonary TB (164 HIV positive, 263 HIV-negative) were collected at three clini-
cal sites in Cape Town, South Africa. Tr-DNA was isolated from 4 ml of EDTA urine us-
ing an in-house method optimised for DNA fragments larger than 38 bp. A rapid double-
stranded primer-based real-time PCR method targeting an MTB-specific direct repeat 
region was applied for Tr-DNA identification. The eluate was tested in triplicate using an 
automated molecular analyser with assay process controls included in each test run. 
The Tr-DNA-based test had a short time to result of 45 minutes including DNA isolation. 
Results: Liquid cultures were performed on 412 of the 428 TB suspects. Of these, 
175/412 (42.5%) were microbiologically positive. Using liquid culture as gold standard, 
the Tr-DNA test showed sensitivity of 42.86% (95% CI: 35.42 – 50.54) and specificity of 
86.61% (95% CI: 83.86 – 92.36). The Tr-DNA test had positive predictive value of 73.53% 
and negative predictive value of 67.74%. Among HIV-infected TB patients, the sensitivi-
ty and specificity were 45.24% and 89.04%, respectively. Combination of smear micros-
copy and Tr-DNA increased the sensitivity to 83.82% (smear microscopy alone was 
75.14%); the specificity remained unchanged (96.61%).  
Conclusions: This multi-centre proof of concept study indicates that Tr-DNA has a high 
specificity and modest sensitivity. Furthermore, future study should be performed on 
larger cohort not restricted to pulmonary TB using fresh urine samples with patient fol-
low up. Although unsuitable for implementation as a stand-alone test, it may have the 
potential, in combination with smear microscopy, to aid TB diagnosis in HIV-endemic 
regions where sputum scarce and extra-pulmonary TB are common. 
Keywords: Pulmonary tuberculosis, urine, transrenal DNA, diagnosis, PCR, HIV 
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1. Introduction 
 
1.1 Tuberculosis  
Tuberculosis (TB) is not a new disease; archaeological evidence shows that TB has 
existed for more than 9000 years [1]. Robert Koch discovered the causative pathogen 
for TB, Mycobacterium tuberculosis (MTB), in 1882 [2, 3]. MTB is a Gram-positive and 
highly aerobic bacterium [4]. Furthermore, MTB is such a well-adapted infectious agent 
that exposure to only a few bacilli are sufficient to cause infection [5]. TB is transmitted 
by droplets produced during coughing and sneezing. This airborne disease primarily 
infects the lungs, and other organs can also later be affected. Furthermore, risk factors 
such as human immunodeficiency virus (HIV) infection, malnutrition, diabetes mellitus, 
alcoholism and malignancy are associated with TB disease development after primary 
infection [6, 7]. In addition, HIV infection also supports the spread of MTB bacilli to other 
body parts [8, 9].  
 
1.2 Epidemiology of tuberculosis 
TB may have killed more people than any other infectious disease. Between 1990 and 
2014, mortality due to TB had declined by 47% [10]. However, TB received widespread 
media attention in 2015 when it killed more people than HIV and became the leading 
infectious cause of death [11]. An estimated 10.4 million new TB cases were reported in 
2015, and an estimated 1.4 million people died from TB-related illness in that year (1 
million HIV-negative and 0.4 million HIV-positive individuals) [12]. At the geographic 
level, the prevalence of TB is high in regions with limited access to resources, such as 
sub-Saharan Africa and Asia [13]. Among other high burden countries, South Africa has 
the highest TB incidence rate, of 834 per 100,000 people [12]. Furthermore, HIV infec-
tion reduces the CD4 T cell count and promotes the growth of MTB [14]. Figure 1.1 
shows the global trends in TB incidence (1990-2014), prevalence, and mortality rates 
(1990-2015). Figure 1.2 shows the estimate of 2014 TB incidence rates/100,000 people. 
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Figure 1.1: Global trends of TB incidence, prevalence, and mortality between 1990 
and 2014 
 
Figure 1.2: Estimated TB incidence rates in 2014 
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1.3 Tuberculosis vaccine 
A TB vaccine could potentially prevent disease transmission by reducing the risk of 
MTB infection and progression to disease from infection. Between 1908 and 1919, Al-
bert Calmette and Camille Guerin developed a live attenuated vaccine from Mycobacte-
rium bovis; the so-called Bacille Calmette-Guerin (BCG) vaccine [15]. Almost a century 
later, the BCG vaccine remains the only TB vaccine available, providing protection for 
children by decreasing MTB infection progression. Although the BCG vaccine protects 
children against disseminated TB and TB-related meningitis during the early childhood, 
it does not protect against pulmonary TB in adults [16]. 
 
1.4 Tuberculosis disease diagnosis 
Primary screening tools 
TB suspects are currently screened using clinical symptoms, such as prolonged cough 
(more than two weeks), night sweats, fever, weight loss, and dyspnea, which are com-
mon among pulmonary TB patients, although not specific [17]. Furthermore, chest X-ray 
(CXR) is a cost-effective method of detecting early signs of disease [18]. CXR is also 
easy to perform and results are quickly available [19]. However, the abnormalities found 
on CXR in TB are not pathognomic, as other respiratory diseases can show similar ab-
normalities [20, 21]. 
 
Smear microscopy 
Smear microscopy is by far the most commonly used TB diagnostic test. It is based on 
the staining of acid-fast bacilli present in sputum. The Ziehl-Neelsen-based method is 
widely used and is a relatively time-consuming procedure. Although inexpensive, the 
method has a low sensitivity (approximately 50%) among culture confirmed TB cases 
[22]. Moreover, smear microscopy has even lower sensitivity among HIV-infected pa-
tients [23]. This low sensitivity further support the TB transmission unnoticed [24]. 
Therefore, sputum smear negative TB cases have an impact on the diagnostic algo-
rithm in resource constrain settings [25].  
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Sputum culture 
To date, sputum culture remians the gold standard for TB diagnosis [26]. However, im-
plementation of culture diagnostics in limited resource settings remains challenging [27]. 
MTB present in sputum is cultivated on Löwenstein-Jensen (LJ)/Middlebrook medium or 
in liquid mycobacterium growth indicator tubes (MGIT) at 37°C for several weeks. MTB 
grows slowly, requiring up to eight weeks for a solid culture and up to six weeks for a 
liquid culture to make a conclusive diagnosis [28]. Furthermore, culture contamination is 
relatively common despite appropriate lab quality management in place [29].  
 
Nucleic acid amplification tests (NAAT) 
Development of rapid molecular tests using sputum has been a breakthrough in TB di-
agnosis [30]. NAAT-based tests such as Xper® MTB/RIF (Cepheid Inc., USA) have 
achieved a sensitivity of 90.4% (95% CI: 89.2 – 91.4) and specificity of 98.4% (95% CI: 
98.0 – 98.7) and can be implemented in resource scarce settings or at the point of care 
(POC) [31-33]. The availability of NAAT-based analysers has made it possible to diag-
nose TB using various sample types, such as biopsies, urine, pus and cerebral spinal 
fluid [34].  
 
Immune response-based diagnostic tests 
The tuberculin skin test (TST) is the oldest and most commonly used immune diagnos-
tic test [35]. Nevertheless, among high-prevalence countries, TST results can be false 
positive due to sensitization with MTB [36]. Interferon-gamma release assays (IGRA) 
such as T-SPOT.TB (Oxford Immunotec, UK), and QuantiFERON®-TB Gold in-tube test 
(Quest Diagnostics, USA) are novel immune-based assays. IGRAs are blood-based 
tests and mainly used for diagnosis of latent TB infection but can also be used to detect 
active disease [37]. However, among high TB-prevalent low and middle-income 
countries, IGRA use has not been shown to be advantagous over the TST [38]. 
Additionally, TB diagnosis made using IGRA do not show any benefit among HIV-
infected patients [39], or among children [40]. Therefore, routine use of IGRA remians 
limited [37]. 
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Antigen-based rapid test 
The low cost, urine-based, lateral flow diagnostic test detects the presence of lipoarabi-
nomannan (LAM) in urine [41]. Although it can be performed at POC in resource-
constrained settings [42], A meta-analysis of the TB-LAM test showed a sensitivity of 13 
– 93% and specificity of 87 – 99% [43]. This wide range of assay performance is mainly 
due to the factors such as CD4 cell count and level of immunosuppression [44]. Test 
performance is limited to HIV-positive patients with a CD4 count below 100 cells/mm3 
[45]. In other words, TB screening is possible among advanced immunosuppressed HIV 
patients using this rapid test [46]. The world health organization (WHO) recommends 
the TB-LAM lateral flow test (Alere, USA) for TB diagnosis and screening among people 
living with HIV [47, 48]. 
 
1.5 Biomarker for tuberculosis diagnosis  
Efforts to develop a novel TB diagnostic test have accelerated in recent years, due to 
involvement from the WHO and non-governmental organisations such as the 
Foundation for Innovative New Diagnostics (FIND) and the Bill and Melinda Gates 
Foundation (BMGF). Blood and urine-based biomarkers are the outcomes of recent ad-
vances in research, and have shown potential for TB diagnosis [49, 50]. However, low 
concentrations of target biomarkers may require larger sample volumes, which is only 
possible when using urine. Moreover, biomarkers present in blood may also be present 
in urine when they can pass the kidney barrier, e.g., cell-free nucleic acid and transrenal 
DNA (Tr-DNA) [51, 52]. Cell-free nucleic acids present in blood and other bodily fluids 
have shown potential for use in the diagnosis of infectious diseases and cancers [53, 
54]. In addition, a urine-based POC test could be used in combination with smear mi-
croscopy or with liquid culture for pulmonary and extra-pulmonary TB suspects [50, 55]. 
 
1.6 Problem statement 
Smear microscopy and liquid culture remain the tests of choice in high-prevalence set-
tings [56]. Due to the nature of TB infection, children and HIV-positive patients are often 
unable to produce sufficient sputum on demand and may require sputum induction to 
provide enough volume for testing [57, 58]. Due to this limitation and the lack of a single 
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test for diagnosis, we currently rely on second and even third diagnostic tests to identify 
all cases of TB [59]. Delay in TB diagnosis and treatment in turn hampers disease con-
trol and increases the public health burden [60, 61]. Therefore, a rapid and easy to per-
form POC test is needed to cover all TB suspects in HIV and TB-endemic areas such as 
South Africa [12]. A urine-based diagnostic test could complete the current diagnostic 
algorithm and cover all groups of patients regardless of their co-infection and age.  
Urine-based molecular TB diagnostic assays have achieved varying sensitivities and 
specificities for both pulmonary and extrapulmonary TB among HIV-positive and nega-
tive cohorts. Meta-analyses of Tr-DNA based tests have shown a sensitivity of 55% and 
specificity of 94% [62].This rather lower assay performance might be due to the use of 
non-standardised Tr-DNA isolation method and MTB target that is amplified in the PCR 
method for TB diagnosis. A Tr-DNA-based diagnostic test is a combination of two steps: 
1) Isolation of Tr-DNA from urine, and 2) amplification of the target-specific DNA. Many 
critical factors are involved that play a role in the development of a robust and reproduc-
ible test, such as reagent quality, isolation method, cost, and the availability of a PCR 
machine for DNA analysis. The Tr-DNA isolation step is essential for targeting and de-
tecting the MTB-specific DNA fragments. There are currently a select few nucleic acid 
isolation kits available for various bodily fluids that require the use of different reagents 
and additional instruments [63]. Therefore, a Tr-DNA method primarily developed and 
optimised for urine could help to isolate target DNA fragments smaller than 200 base 
pairs (bp) in size [64, 65]. 
Moreover, the availability of molecular tests remains limited to resource-rich settings 
due to the requirements for infrastructure and a skilled lab technician to perform the 
tests. Implementation of a novel molecular assay for diagnosis in limited resource set-
tings could improve disease control [66]. 
 
1.7 Rationale, goals, and objectives 
1.7.1 Rationale 
Recent advances in diagnostic test development and their availability in limited resource 
settings have aided in the control of TB disease [35, 67]. A test using a sample type 
other than sputum could further improve diagnostic ability and control TB in highly en-
demic countries. The ability to collect a larger urine volume, in comparison to other bodi-
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ly fluids, is advantageous. The urine sample collection procedure is non-invasive, and 
sample collection is also possible from sputum-scarce HIV-infected individuals and chil-
dren. 
Advancement in the fields of medical device technology and molecular biology have 
made it possible to bring lab-based molecular diagnostic tests to the POC [68]. Fur-
thermore, molecular tests provide more conclusive results in comparison to immune-
based assays, allowing clinical decisions to be made based on test results [69]. In addi-
tion, urine-based molecular assays targeting the MTB-specific DNA fragments can be 
useful for TB diagnosis and therapy monitoring [70]. The availability of a TB molecular 
test at smear microscopy centres or HIV clinics could further improve TB control [71]. 
1.7.2 Goals 
To make available a urine-based rapid molecular test for the diagnosis of pulmonary 
and extra-pulmonary TB with potential for implementation at POC settings in areas of 
high TB prevalence. 
1.7.3 Objective 
Main objective  
The main objective of this study is to evaluate a urine-based rapid molecular diagnostic 
test for pulmonary TB using an automated molecular analyser in a patient cohort from 
Cape Town, using a cross-sectional study design  
Secondary objectives 
i) Optimisation and standardisation of an in-house developed Tr-DNA isolation 
method. 
ii) Validation of a rapid molecular assay based on POC Alere q by comparing 
this with standard lab-based PCR methods. 
iii) Definition of the target population where sputum-based diagnostic tools fail, 
and determining whether the Tr-DNA based assay brings an advantage. 
iv) Comparison of the assay performance among HIV-positive and negative TB 
suspects. 
v) Determine the effects of urine characteristics on assay performance. 
The materials and methods used in this study will be described in chapters 2 and 3, re-
spectively. The results obtained will be presented in chapter 4.  
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2 Materials  
 
2.1 Instruments, commercial kits, reagents and consumables 
During the study different sets of instruments, commercial kits, reagents and consuma-
bles were used. Detailed information about particular material is mentioned in appropri-
ate tables below.  
 
Table 2.1: List of instruments used for the Tr-DNA isolation method optimisation 
and evaluation of novel Tr-DNA assay. 
Instrument name Supplier/Manufacturer 
7500 Real-Time PCR System Thermo Fischer Scientific, Waltham, USA 
NanoDrop 3300 Thermo Fischer Scientific GmbH, Dreieich Germany 
Centrifuge Eppendorf, Wesseling-Berzdorf, Germany 
DNA electrophoresis system VWR International, Dresden, Germany 
Gel imager Bio-Rad Laboratories GmbH, Munich, Germany 
Biosafety cabinet Thermo Fischer Scientific GmbH, Dreieich Germany 
Syringe pump: PHD ultra infuse Harvard Apparatus GmbH, Hugstetten, Germany 
Thermomixer Eppendorf, Wesseling-Berzdorf, Germany 
Pipettes Eppendorf, Wesseling-Berzdorf, Germany 
Water bath Memmert, Schwabach, Germany 
Refrigerator Liebherr, Biberach an der Riss, Germany 
Alere q Analyser Alere Technologies, Jens, Germany 
GeneXpert XVI Cepheid, Sunnyvale, USA 
BAC- TEC MGIT 960 system BD Diagnostics, Franklin lakes, NJ, USA 
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Table 2.2: List of commercial kits used for the Tr-DNA isolation method optimisa-
tion and evaluation of novel Tr-DNA assay. 
All commercial kits were within their shelf life and analysis performed according to manufacturer instruc-
tion.  
Kit name Supplier/Manufacturer 
PicoGreen
®
 dsDNA Assay Kit Thermo Fischer Scientific GmbH, Dreieich Germany 
Combur-Test
®
 10 dipstick test Roche Diagnostics GmbH, Grenzach-Wyhlen, Germany 
QuantiTect SYBR Green PCR Kit Qiagen GmbH, Hilden, Germany 
QIAamp Circulating Nucleic Acid Kit Qiagen GmbH, Hilden, Germany 
E. coli plasmid (pEX vector) Eurofins, Jena, Germany 
GeneXpert MTB/RIF Cepheid, Sunnyvale, USA 
MTBDR plus line probe assay Hain Lifescience, Nehren, Germany 
 
Table 2.3: List of reagents and consumables used for the Tr-DNA isolation meth-
od optimisation and evaluation of novel Tr-DNA assay. 
All reagents were within their shelf life and to avoid contamination, the reagents were aliquoted into 
smaller portion and stored according to manufacturer instruction till further use.  
Reagent/Consumable name Supplier/Manufacturer 
BD Falcon tubes (15 ml, 50 ml) VWR International, Dresden, Germany 
Centrifuge tubes (1.5 ml, 2 ml) VWR International, Dresden, Germany 
Pipette tips VWR International, Dresden, Germany 
Syringe with Luer taper VWR International, Dresden, Germany 
Mobicol classic with screw cap with-
out filter 
Mobitec GmbH, Göttingen, Germany 
Mobitec filter (50 µm) Mobitec GmbH, Göttingen, Germany 
H37Rv genome bacterial qDNA Tebu-bio GmbH, Offenbach, Germany 
PBS w/o calcium, w/o magnesium Thermo Fischer Scientific GmbH, Dreieich, Germany 
Lambda DNA Thermo Fischer Scientific GmbH, Dreieich, Germany 
Agarose for gel electrophoresis Thermo Fischer Scientific GmbH, Dreieich, Germany 
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Reagent/Consumable name Supplier/Manufacturer 
96-well plates Thermo Fischer Scientific GmbH, Dreieich, Germany 
Primers, DNA fragments Eurogentec GmbH, Cologne, Germany 
Sarstedt Monovette (10 ml) Sarstedt, Nümbrecht, Germany 
Isopropanol Carl Roth GmbH, Karlsruhe, Germany 
Nuclease-free water (molecular 
grade) 
Carl Roth GmbH, Karlsruhe, Germany 
Binding buffer Alere Technologies, Jena, Germany 
Capture matrix Alere Technologies, Jena, Germany 
Washing buffer Alere Technologies, Jena, Germany 
DNA-Exitus VWR Darmstadt, Germany 
 
2.2 DNA fragments 
DNA fragments of varying lengths (38 bp, 50 bp, 75 bp, 100 bp, 150 bp, and 200 bp) 
and MTB reference standard H37Rv genomic DNA (gDNA) were used for experiments. 
The DNA fragments were specific for the MTB gene IS6110 and contained target specif-
ic primer binding sites at the 5’ and 3’ ends. Spacers of varying lengths were used to 
achieve the desirable synthetic DNA fragment length. The ultra-short DNA fragments 
were ordered as an oligonucleotide (single-stranded DNA of 38 bp and 50 bp), and 
corresponding pairs annealed to form double-stranded DNA. The longer DNA fragments 
(75 bp, 100 bp, 150 bp, and 200 bp) were cloned in E. coli plasmids (pEX-A vector, Eu-
rofins) and were replicated using clone culture. The final concentration of DNA frag-
ments was determined using the PicoGreen® method on a NanoDrop analyser (Thermo 
Scientific, Germany) according to manufacturer instructions. The synthesised fragments 
were diluted, aliquoted, and stored for further use at -80°C. Two different sets of forward 
and reverse primers were designed for IS6110 to avoid cross contamination when test-
ing with clinical samples.  
 
26 
 
2.3 Urine samples from healthy control cohort 
Five voluntary co-workers (healthy) at Alere Technologies GmbH, Jena, Germany, pro-
vided up to 1000 ml of control urine. The urine samples were aliquoted into 50 mL fal-
con tubes and stored between -70°C and -80°C for further use. No data regarding the 
donors were collected. The in-house Tr-DNA isolation method was developed and opti-
mised using this control urine. 
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3 Methods 
3.1 Study design 
3.1.1 Study cohort 
Patients with suspected pulmonary tuberculosis (PTB) were consecutively recruited 
from July – November 2013 at three different clinical sites (Gugulethu, Langa, and Van-
guard) in Cape Town, South Africa. Demographic and clinical characteristics were 
recorded for each participant using the case reporting form (CRF). Body weight and 
height was also recorded for body mass index (BMI) calculation. For the detailed CRF, 
please refer to Appendix 1. 
 
3.1.1.1 Inclusion/exclusion criteria 
The inclusion criteria for the study were as follows.  
 Adult pulmonary TB suspects (≥ 18 years of age);  
 Presence of clinical symptoms:  
o for HIV-negative participants: cough for more than two weeks, night 
sweats, weight loss, malaise (general feeling of being unwell), fever ≥ two 
weeks, temperature ≥ 38°C, chest pain, or haemoptysis (coughing up of 
blood);  
o for HIV-positive participants: at least one of the abovementioned 
symptoms; 
 Providing a signed informed consent form; 
 Participants did not plan to leave the municipal area during the following two 
months; 
 Willingness to undergo HIV testing; and 
 Able to provide at least two sputum samples (volume ≥ 1.5 ml per sample) and 
60 ml of spot urine. 
The exclusion criteria for the study are outlined below.  
 Pregnancy; 
 TB therapy more than one week in duration; and  
 Presence of non-TB mycobacterial infection. 
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3.1.2 Study period and sites 
For the evaluation of the novel molecular assay, a cross-sectional study was designed. 
Urine samples were processed for Tr-DNA isolation in May – August 2015 at the Re-
search Centre Borstel, Germany, and Alere Technologies, Jena, Germany. All PCR ex-
periments were performed during October 2015 – November 2016 at Alere Technolo-
gies, Jena, Germany.  
3.1.3 Ethical approval 
Ethical approval was received from the Health Sciences Faculty Research Ethics Com-
mittee at University of Cape Town and approved under number IRB# IRB00001938. 
Participants were insured through Federal Wide Assurance # FWA00001637. Written 
informed consent was collected from each participant.  
3.1.4 Sample collection, storage and processing  
The participants provided two spot sputum samples (volume ≥ 1.5 ml per sample) in 
sterile container during their initial clinic visit, with a one-hour interval between samples. 
When possible, a third sputum sample was also collected for the biobank and stored at -
80°C. Eight ml EDTA blood was also collected. 50 ml spot urine was collected in a ster-
ile container holding 25 mM EDTA to prevent DNA degradation, and the sample was 
finally stored at -80°C. Urine samples were shipped on dry ice to the Research Centre 
Borstel, Germany, for further processing. Before use, the frozen samples were brought 
to room temperature using a thermal heater. The flow diagram (Figure 3.1) below pro-
vides an overview of the patient enrolment process and the samples collected.  
 
 
Figure 3.1: Overview of patient study enrolment and sample collection (blood, 
urine, and sputum) 
 
Screening of  
TB suspects  
and TB patients 
Not enrolled 
Informed Consent Enroll 
Basic Patient Data 
Collection 
Collect sputa  
≥1.5 ml each  
(one hour apart) 
Collect 50 ml urine 
Collect 8ml blood 
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3.2 Sputum microbiology 
The initial spot sputum was labelled and sent to the National Health Laboratory Service 
(NHLS), a centralised and accredited microbiology lab in Cape Town, South Africa. The 
second sputum sample was stored raw at -80°C for future testing (as a precaution 
against errors or contamination issues). All samples were processed using standardised 
and quality assurance procedures. The sputum samples were decontaminated using a 
N-acetyl-L-cysteine and sodium hydroxide (NALC-NaOH) method, according to the My-
cobacteriology Laboratory Manual [72]. Decontaminated and centrifuged deposits of 
sputum samples were re-suspended in phosphate buffer (pH 6.8) and processed sam-
ples were divided into three equal portions for liquid culture, Xpert MTB/RIF, and smear 
microscopy tests. Liquid culture was performed using mycobacterial growth indicator 
tubes (MGITs) in the BACTEC MGIT 960 System (BD Diagnostics, USA) and incubated 
at 37°C for six weeks/42 days. Liquid culture positive samples underwent then 
Genotype MTBDR plus line probe assay (Hain Lifescience, Nehren, Germany). Xpert 
MTB/RIF assay was performed according to the procedure previously described [73]. If 
possible, same day sputum smear microscopy was performed and semi-quantitative 
grading (scanty, 1+, 2+, and 3+) was assigned to observed bacilli, according to the 
WHO/International Union Against Tuberculosis and Lung Disease procedures [74]. The 
sputum smear microscopy results were not considered to define TB status.  
The final results from MGIT and Xpert were taken into consideration for TB diagnosis. 
However, Tr-DNA assay outcomes were compared to the gold standard liquid MGIT 
culture only. Discordant results (liquid culture negative and Xpert positive) were sepa-
rately taken into consideration for sensitivity and specificity determination. Figure 3.2, 
shows the algorithm schematic used for sputum microbiology. 
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Figure 3.2: Schematic of diagnostic algorithm used for microbiology testing using 
sputum 
Liquid culture and Xpert MTB/RIF were performed on the day of sputum collection, and if possible smear 
microscopy was also performed on the same day. However, smear microscopy results were not consid-
ered for TB diagnosis.  
 
3.3 HIV screening and CD4 cell count 
Participants without known HIV status were tested using serological test at local clinics 
after appropriate counselling. The ABON HIV1/2/O Tri-Line Human Immunodeficiency 
Virus Rapid Test (ABON Biopharm (Hangzhou) Co. Ltd, China) and First Response HIV 
1-2.O Rapid Whole Blood Test (Premier Medical Corporation Ltd, Nani Daman, India) 
were used to determine HIV status. The CD4 cell count (measured during the last six 
months) was obtained from the clinical records for HIV-positive patients. 
 
Collect Sputa  
( ≥1.5 ml) 
Sputum 1 
NALC-NaOH 
decontamination 
MGIT 
Geno type MTBDR 
plus 
Xpert MTB/RIF 
RIF Sen RIF Res 
Smear Microscopy 
Sputum 2 
Store raw at  
 -80°C 
Sputum 3 
Biobank store at  
-80°C 
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3.4 Dipstick test for urine characterisation  
Frozen urine samples were thawed using a thermal heater and homogenised by invert-
ing the tube several times. All urine samples underwent visual examination for colour 
and clarity. Furthermore, each urine specimen was characterised using the Combur-
Test® 10 dipstick test (Roche Diagnostics GmbH, Grenzach-Wyhlen, Germany). This 
test is a lateral flow test and determines parameters such as density (specific gravity), 
pH, leukocyte presence, nitrite, protein, glucose, ketone, urobilinogen, bilirubin, and 
erythrocyte presence in semi-quantitative or qualitative manners. The tests were con-
secutively performed in a biosafety cabinet to avoid cross contamination and for safety 
reasons.  
 
3.5 DNA concentration measurement using the PicoGreen method 
Total DNA content was measured for the urine eluate using the PicoGreen® ds DNA 
Assay Kit (Thermo Scientific, USA) on the NanoDrop 3300 analyser (Thermo Scientific, 
USA) according to the manufacturer’s instructions for DNA quantification. The DNA 
eluate was diluted 1:5 using the supplied buffer. The DNA concentration value (ng/ml) 
was calculated using a standard curve generated with lambda DNA (supplied by the 
manufacturer in the following concentrations: 5 ng/ml, 10 ng/ml, 25 ng/ml, 100 ng/ml, 
500 ng/ml, and 1000 ng/ml). For the setup of the standard curve, all DNA concentra-
tions were measured in five replicates. Each DNA eluate measured in three replicates 
together with a negative control (molecular grade water). DNA concentration of the elu-
ate was calculated using the standard curve.  
 
3.6 Polymerase chain reaction using the standard PCR cycler approach 
The classical three step RT-PCR method using SYBR® Green reagents on the 7500 
real-time (RT) PCR analyser (Thermo Fischer Scientific, USA) was performed for Tr-
DNA analysis. Table 3.1, below, shows the pipetting scheme used for the PCR master 
mix. The PCR steps consisted of an initial denaturation phase for 15 min at 95 °C 
followed by cyclic denaturation for 15 sec at 95 °C, annealing for 30 sec at 62 °C and 
elongation for 30 sec at 72 °C. The forward primer (5’-GACGCGATCGAGCAAGCC-3’) 
and reverse primer (5’-TCTTGTTGGCGGGTCCAG-3’) were designed for the highly 
conservative MTB-specific insertion sequence (IS) 6110, and were the same length (18 
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nucleotides) [65]. The Ct-value for the PCR reactions were calculated using the 
baseline of cycle 3-15 and a threshold of 50,000 relative fluorescence units (RFU).  
 
Table 3.1: Reaction mix required for PCR targeting the IS6110 region of MTB 
Reagent 
Volume in µl 
(eluate: 20 µl) 
Volume in µl 
(eluate: 40 µl) 
Volume in µl 
(eluate: 10 µl) 
Nuclease-free water 24.0 4.0 34.0 
SYBR Green master mix 50.0 50.0 50.0 
Forward primer (0.3 µM) 3.0 3.0 3.0 
Reverse primer (0.3 µM) 3.0 3.0 3.0 
DNA fragments/ H37rv/nuclease-free water 20.0 40.0 10.0 
Final volume 100.0 100.0 100.0 
 
To calculate PCR efficiency, the Ct-values were plotted against the log concentration of 
the amplified copies. PCR efficiency (E) was calculated according the following formula:  
E = 10(−1 b⁄ ) − 1 
where “b” represent slope obtained from standard curve by plotting the log of the start-
ing quantity of DNA fragments or genomic DNA (gDNA) against the cycle threshold (ct) 
value obtained during amplification [75]. All qPCR experiments were evaluated using 
the Applied Biosystems 7500 software version 2.0.6. 
 
The delta Ct-value is a good indicator of the efficiency of the nucleic acid isolation 
method. The delta Ct-value is the Ct difference between the values measured for inhibi-
tion control and the urine eluate. The larger delta Ct-values indicates a higher level of 
PCR inhibition, and the lower values indicate higher PCR efficiency. Delta Ct values 
were calculated for all DNA fragments for both methods using following formula [76]: 
∆ 𝑐𝑡 = 𝑐𝑡 (𝑇𝑆) − 𝑐𝑡 (𝑅𝑆) 
Where: TS = Test sequence, RS = Reference sequence (e.g., positive control or inhibi-
tion control) 
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3.7 PCR analysis of synthetic DNA fragments 
The functionality of MTB-specific IS6110 synthesised DNA fragments (38 bp, 50 bp, 75 
bp, 150 bp, and 200 bp) was confirmed by target-specific PCR using the SYBR Green 
method on an RT-PCR AB cycler. For quality and stability, the DNA fragments were 
analysed in a logarithmic concentration series (10 cp, 102 cp, 103 cp, 104 cp, 105 cp, 106 
cp, and 107 cp) by dilution into nuclease-free water, and then measured in triplicates. 
Genomic DNA from the MTB reference strain H37Rv was run as the PCR positive 
control; a negative control was also run in all PCR experiments. 
 
3.8 Gel electrophoresis 
Gel electrophoresis is a classic tool used to confirm the specificity of generated PCR 
products by measuring their particular lengths. The PCR products were loaded into a 
2.5% w/v agarose gel prepared according to the manufacturer’s instructions (Thermo 
Fisher Scientific, USA). 1.5 µl of 50 bp ladder was added to 5 µl bromophenol blue and 
run as a base pairs marker in the gel. Furthermore, 25 µl of PCR product was mixed 
with 5 µl of bromophenol blue, and 15 µl of sample was applied into the gel for PCR 
product analysis. Electrophoresis was run at 130 volts for 45 minutes using the DNA 
electrophoresis system (VWR International, Germany); the gel was then analysed using 
a gel imager (Bio-Rad, Germany).  
 
3.9 QIAamp circulating nucleic acid method  
The QIAamp circulating nucleic acid kit was used as a reference method to compare 
and optimise the in-house Tr-DNA isolation method. This commercially available kit can 
isolate circulating cell-free nucleic acids from various bodily fluids, including blood, 
plasma, serum, and urine. The isolation method is comprised of four steps: lysis, bind-
ing, washing, and elution. The kit provides selective binding to a silica-based membrane; 
nucleic acids specifically bind to the QIAamp mini column, while impurities such as PCR 
inhibitors, divalent cations and proteins can be completely removed in three washing 
steps. The pure nucleic acids are the eluted using an elution buffer. The purified 
concentrated circulating DNA and RNA can be used for downstream RT-PCR analysis. 
A sample volume of up to 5 ml can be isolated using the Qiagen method, with a flexible 
elution volume between 20 and 150 µl.  
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Figure 3.3, below, shows the material required for circulating nucleic acid isolation using 
the Qiagen method. In order to set up the filtration unit, the Leur taper syringe (B) with 
screw cap must be attached to the mobicol column. The QIAamp mini column can now 
be inserted into the mobicol column (A). The syringe plunger is then removed and the 
binding suspension is transferred in the syringe. The plunger is inserted into the syringe 
and the suspension is filtered by applying pressure to the plunger. The waste can be 
collected in 15 ml falcon tubes. 
 
 
Figure 3.3: Material required to perform nucleic acid isolation using the Qiagen 
method  
Mobicol system (A), 10 ml syringe with Luer taper (B), micro centrifuge tube (C), and QIAamp mini col-
umn (D) 
 
  
A 
B 
C 
D 
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The standard QIAamp protocol was modified for use with 4.0 ml urine, as shown in the 
flow diagram, below (Figure 3.4). 
 
Figure 3.4: Overview of nucleic acid isolation protocol using the Qiagen method 
(QIAamp)  
 
3.10 In-house Tr-DNA isolation method  
In-house developed Tr-DNA isolation method was developed and optimised to enrich 
ultrashort DNA fragments (≥ 38 bp) from large urine volumes (up to 4 ml) including 
human and pathogen-specific DNA. To amplify pathogen-specific DNA fragments from 
the isolated total DNA, the development of a target specific PCR method was essential. 
The in-house Tr-DNA isolation method was designed and developed to enable i) en-
richment of ultrashort DNA fragments from large urine volumes, and ii) simplification of 
DNA isolation and amplification/detection for implementation in limited-resource settings. 
The detailed steps required for the manual isolation, including the materials and solu-
tions used, are shown in Figure 3.5. 
 
 
Lysis Step 
•4 mL Urine 
•add 4 mL Lysis buffer ACL 
•add 1 mL ATL buffer 
•add 500 µl Proteinse K solution, mix, vortex and incubate for 30 min at 60°C  
Binding Step 
•add 9 mL of Binding buffer ACB, vortex 
•incubate for 10 min at -25°C 
•QIAamp mini spin filtration 
Washing 
Step 
•add 600 µl of washing buffer ACW1, centrifuge for 1 min at 8000 rpm 
•add 750 µl of washing buffer ACW2, centrifuge for1 min at 8000 rpm 
•add 750 µl of Ethanol, centrigufe for 1 min at 8000 rpm and 3 min at 13200 rpm 
•dry at 55°C for 20 min 
Elution Step 
•add 50 µl Elution buffer AVE 
•incubate for 3 min at room temperature, centrifuge for 3 min at 13200 rpm  
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Figure 3.5: Materials required to perform manual nucleic acid isolation using the 
in-house method 
Mobicol system (A), 10 ml syringe with Luer taper (B), and 2.0 ml microcentrifuge tube (C) 
 
The syringe pump for the isolation process was implemented for ease of handling and 
to increase the sample throughput. Process atomisation enabled the isolation of up to 
10 samples in parallel (10 syringes). The total turn-around time (TAT) was reduced for 
the whole assay. The Figure 3.6 shows the syringe pump with 10 different urines being 
isolated in parallel, which required a total of approximately three minutes.  
 
A 
B 
C 
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Figure 3.6: Tr-DNA isolation using a syringe pump with a modified stand for verti-
cal positioning to accommodate 10 samples 
The 10 mL Leur lock syringe was used for isolation. The syringe pump was set at a force level of 50% 
and a constant rate of 3 ml/min. The isolation was performed under a class III biosafety cabinet. 
 
3.10.1 Binding and elution principle of the in-house method 
The in-house method uses capture matrix and binding buffer. This method, unlike the 
Qiagen kit, does not contain a lysis step. The standard capture matrix usually consists 
of silicates (Si(OH)4), polysaccharides (dextran, Sepharose a cross-linked agarose, or 
cellulose) or synthetic polymers (polyvinyl alcohol). These matrices have free hydroxyl 
(OH) groups that are modified and bind DNA molecules using their functional groups. 
The chaotropic agent present in the binding matrix desaturates biomolecules by inter-
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rupting the hydration shell around the DNA/RNA. Furthermore, positively-charged ions 
enable a cation bridge to form between the negatively-charged capture matrix and the 
negatively-charged DNA backbone in high salt concentrations. The DNA backbone and 
the surface of the capture matrix build an electrostatic bond. The washing buffer (80 mM 
potassium acetate, 8.3 mM Tris-HCl (pH 7.5), 40 μM EDTA and 70% ethanol) removes 
the residual inhibitors from the sample without losing the DNA bound to the capture 
matrix. The ethanol in the wash buffer acts as a precipitant and helps the DNA 
backbone adhere to the capture matrix. In the final step, nuclease-free water breaks the 
bond between the capture matrix and the DNA. The free DNA can now be eluted for 
downstream analysis. Figure 3.7 shows the DNA binding principle for the in-house 
method. 
 
 
(Source: Promega) 
Figure 3.7: Representation of DNA binding principle for the in-house method us-
ing the capture matrix 
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3.10.2 In-house Tr-DNA isolation method optimisation 
The Tr-DNA isolation method, capable of capturing shorter DNA fragments (> 75 bp) 
was optimised for ultrashort fragments (≥ 38 bp) using the previously described meth-
od [70]. The in-house developed Tr-DNA isolation method was compared with the 
commercially available QIAamp Circulating Nucleic Acid Kit. The performance charac-
teristics of both approaches (Qiagen and in-house) were analysed using different sets of 
experiments to optimise Tr-DNA isolation.  
Inhibition of the PCR reaction is the main concern for molecular assays, and removing 
inhibitors in pre-PCR steps is needed to keep PCR performance high. DNA capture effi-
ciency and the effect of total DNA content on PCR performance were taken into consid-
eration for in-house method optimisation. The entire optimisation effort was divided into 
three major groups: i) reagent optimisation, ii) process optimisation, and iii) elution opti-
misation. The optimised method should increase PCR efficiency, stablise the isolation 
process, and reduced the degree of PCR inhibition. 
 
3.10.2.1 Optimisation of urine and reagent volume 
The urine and reagent volume required for Tr-DNA isolation were then optimised for the 
in-house method. Urine volumes of 4.0, 2.0, 1.0, and 0.5 ml were used for optimisation. 
The assay reagents for the in-house developed method were also reduced according to 
the urine volume used. 25 µl of (100 cp/µl) 50 bp DNA fragment was spiked into each 
volume using two different urine samples. Each urine sample was isolated in duplicates, 
and each eluate was further measured in duplicates using the SYBR Green-based PCR 
method. From 50 µl of eluate, 10 µl of eluate was added to 90 µl of master mix solution 
for the PCR process. For the positive control, 10 µl of (100 cp/µl) 50 bp DNA fragments 
was spiked into nuclease free water. Table 3.2 summarises the reagent volumes re-
quired for different urine volume. 
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Table 3.2: Reagent volumes required for different urine volume isolation using the 
in-house method 
Urine volume (ml) Binding buffer (ml) Capture matrix (ml) 
DNA fragments 
(50 bp, 100 cp/µl) 
4 6 1 25 µl 
2 3 0.5 25 µl 
1 1.5 0.25 25 µl 
0.5 0.75 0.125 25 µl 
 
3.10.2.2 Isolation method ability to recover DNA from spiked urine 
Up to five urine samples were spiked with three different concentrations (100 cp/µl, 
1000 cp/µl, and 10,000 cp/µl) of synthetic DNA fragments (38 bp, 50 bp, 75 bp, 100 bp, 
150 bp, 200 bp), and H37Rv gDNA to assess the isolation performance of the in-house 
method. Briefly, 25 µl of DNA fragments or H37Rv gDNA was added to 4 ml of urine. 
DNA isolation was performed on the same spiked samples for the in-house and the Qi-
agen methods. DNA was recovered in 50 µl of eluate. 20 µl of eluate was used for the 
SYBR Green PCR analysis to compare method performance regarding DNA yield and 
reproducibility. In total 100 µl of final PCR volume was analysed in duplicates. Inhibition 
control was performed in parallel to monitor the PCR process and reagent quality. 
 
3.10.2.3 Influence of inhibitors and urine samples on PCR efficiency 
The DNA eluate isolated using the Tr-DNA method may have carried unknown PCR 
inhibitors, which could have originated from the isolation method or from the sample 
itself. Thus, the potential effect of the inhibitors on PCR efficiency was evaluated from 
six different urine samples. Control urine eluates were spiked with DNA fragments of 
different sizes (38 bp, 50 bp, 75 bp, 100 bp, 150 bp, 200 bp), and H37Rv gDNA. 1 µl of 
DNA fragments was added to form a concentration of 1000 cp for inhibition control. A 
negative control was run in each PCR experiment. In total, 100 µl of final reaction vol-
ume was analysed using the SYBR Green-based PCR method. Each urine eluate was 
measured in duplicate.  
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3.10.2.4 Influence of eluate volume on PCR efficiency 
The level of PCR inhibition was further investigated by analysing eluate volumes of 10, 
20 and 40 µl from three urine samples, which were processed using the in-house meth-
od. 25 µl of 75 bp of DNA fragment (1000 cp/µl) was spiked directly into the PCR solu-
tion. The SYBR Green-based PCR method was used for analysis. All samples were 
measured in triplicates. Table 3.3 shows the pipetting scheme for PCR samples.  
 
Table 3.3: Pipetting scheme for different eluate volumes  
Sample 
Master mix 
(µl) 
Urine eluate 
(µl) 
Molecular 
water (µl) 
DNA fragments 
(µl) 
Total      
volume (µl) 
10 µ eluate 60 10 20 10 µl (10 cp/µl) 100 
20 µl eluate 60 20 10 10 µl (10 cp/µl) 100 
40 µl eluate 60 40 N/A 1 µl (1000 cp/µl)* 101 
Positive control 60 N/A 30 10 µl (10 cp/µl) 100 
Negative control 60 N/A 40 N/A 100 
*A higher concentration of the DNA solution was used in order to achieve the final PCR volume of 100 µl 
for 40 µl of urine eluate, N/A = not applicable (not performed) 
 
3.10.2.5 Influence of eluate dilution on PCR efficiency 
Together with a reduction in eluate volume, the eluate dilutions could aid in reducing the 
effect of PCR inhibitors. Therefore, five different urine samples spiked with 250 copies 
of H37Rv gDNA were isolated using in-house method to analyse the effect of eluate 
dilution on PCR efficiency. 20 µl from the total 50 µl eluate volume was diluted in series 
of 1:2, 1:4, 1:8, and 1:16 using molecular grade water. Urine was isolated in duplicates, 
and each isolate was twice measured to allow analysis of reproducibility and method 
reliability. The PCR positive control H37Rv gDNA was diluted in same range as the 
urine eluate in order to monitor the effect of diluation. In total, 100 µl of sample volume 
was used for the PCR reaction (80 µl master mix and 20 µl eluate).  
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3.10.3 Tr-DNA isolation using an optimised in-house developed method 
Tr-DNA isolation was then performed using the optimised in-house developed method. 
6 ml of lysis/binding buffer and 1 ml of binding matrix were added to 4 ml of urine, the 
solution was mixed gently and transferred to the filter column (pore size 10 μm). The 
pellet was twice washed using 80 mM potassium acetate, 8.3 mM Tris-HCl (pH 7.5), 40 
μM EDTA, and 70% ethanol solution, to eliminate residual inhibitors from urine and 
buffer. The DNA was eluted in two steps in a final volume of 75 μl of molecular grade 
water. Each urine sample was isolated in duplicates and the DNA eluate pooled and 
stored at -80°C until final analysis. Urine from healthy volunteers was isolated together 
with clinical samples to check for cross contamination and purity of reagents at the be-
ginning and end of the day. As a positive control, urine was spiked with 35 μl of H37Rv 
gDNA. As a negative control, normal urine was isolated. All control samples were 
isolated in duplicate. The in-house method protocol using 4 ml of urine is shown in the 
flow diagram, below (Figure 3.8). 
 
 
Figure 3.8: Overview of Tr-DNA isolation protocol for the in-house method  
 
Binding Step 
• 4 mL Urine 
• add 6 mL of Binding Buffer 
• add 1 mL of Capture Matrix in 15 ml falcon tube 
• pass through 10 µm filter column 
Washing Step 
• add 400µl wash buffer to the column and centrifuge for 1min at 6.000 rcf 
• add 400µl wash buffer to the column and centrifuge for 1min at 9.000 rcf 
• centrifuge the column again for 2min at 9.000 rcf to remove residual 
Elution Step 
• add 40 µl nuclease-free water and wait 1 minute, centrifuge for 1min at 16.000 rcf 
• add 35 µl nuclease-free water and wait 1 minute, centrifuge for 1min at 16.000 rcf. 
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3.11 Novel and rapid polymerase chain reaction using an automated ana-
lyser 
The double-stranded primer-based PCR method works well as a lab-based real-time 
PCR cycler. To bring the lab-based molecular test to resource-limited settings, we need 
to implement the assay using the portable and automated POC-capable Alere q analys-
er. Different assay-related aspects were optimised, e.g., primer: quencher ratio, number 
of PCR cycles, PCR steps, annealing and elongation temperatures, and duration of 
each phase. The novel assay using the Alere q must be validated by comparison to the 
existing SYBR Green-based PCR protocol mentioned earlier [70]. 
A compact, portable molecular analyser called the “Alere q” analyser is capable for use 
at point of care (POC). Once the sample has been applied to the single-use cartridge, 
the analyser automatically performs amplification and detection, including data analysis. 
The cartridge is a closed system, so that waste remains within the cartridge. The image 
below (Figure 3.9) shows the Alere q analyser and the cartridge used.  
 
(Source: Alere) 
Figure 3.9: Automated molecular analyser the “Alere q” and a single-use assay 
cartridge  
The analyser automatically performs all of the required steps and displays the results on the touch screen. 
No user input is needed.  
 
For the detection of MTB-specific Tr-DNA, a real-time non-probe-based PCR using a 
double-stranded primer (DSP) was implemented using the Alere q. This PCR approach 
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was initially developed for detection of HIV [77]. In the DSP-based PCR, a fluorescent 
dye is attached to the 5’ end of a forward primer, and a reverse complementary oligonu-
cleotide is labelled with a Black Hole Quencher dye (BHQ) at the 3’ end. The forward 
primer binds in solution to its matched reverse oligonucleotide. The quencher prevents 
the initial fluorescence. However, during amplification in the presence of the target, the 
bond between the double-stranded primer and the quencher breaks and the fluores-
cently-labelled primer attaches to the target template [77]. This binding then shows an 
increase in fluorescence signal.  
This technology was applied to the Alere q for the detection of the MTB-specific direct 
repeat (DR) region using a Cy5-labelled forward primer and a BHQ-labelled 
complementary reverse primer. The temperature of the annealing phase was adjusted 
to the primer’s melting temperature (Tm) so that the balance was shifted to the primer-
template hybrids instead of the primer-quencher hybrids. Figure 3.10, below, is a sche-
matic representation of DSP-based PCR. 
 
 
Figure 3.10: Schematic diagram of the double-stranded primer-based PCR princi-
ple  
The forward and reverse primers are designed to target ultra-short DNA fragments (≥ 38 bp). In the ab-
sence of a target amplicon in the reaction solution, the fluorescence signal from the forward primer is 
blocked by the BHQ dye, which is attached to the 3’ end of the reverse complementary primer.  
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3.11.1 Array layout for the Alere q cartridge 
The Alere q cartridge contains a microarray chip on which target-specific probes, as well 
as controls, are spotted in triplicates. The defined index spots for data analysis are spot-
ted five times (Figure 3.11). The microarray is placed in the reaction chamber where the 
amplification reaction takes place. Internal process controls for the Tr-DNA assay were 
implemented using the competitive reporter monitored amplification (CMA) method [78].  
 
Figure 3.11: Array layout for a single-use Alere q cartridge microarray chip 
The spots coloured violet (#1) show the index spots for orientation, green (#2) show the negative 
hybridization control, blue (#3) show the non-target-specific positive hybridization control, and brown (#4) 
show the target-specific internal process control. 
 
No fluorescence signal was expected for the negative hybridization control. A 
fluorescence signal at a defined level has to be detected throughout the assay perfor-
mance for the positive hybridization control. The internal process control is required to 
lie within the predefined Ct and lift range to provide a valid test result. Initially, all re-
verse oligonucleotides present in the reaction solution have Cy5 attached to the 5’ and 
3’ ends. These bind to their complementary immobilised probes on the array, and no 
signal is given. Figure 3.12 represents the amplification curve generated for the internal 
process control during the Tr-DNA assay. 
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Figure 3.12: Process controls implemented in the Tr-DNA assay 
The positive control should remain positive throughout the assay duration, while negative control should 
not give any unspecific signal. The signal from internal process control (IPC) starts with 100% and as 
more and more process control amplifies during the assay the signal drops. The IPC should be with in 
predefined range. These controls make the assay more robust to unwanted amplification and PCR inhibi-
tion.  
3.11.2 PCR primer design for the DR target region 
The forward and reverse primers targeting the Mycobacterium tuberculosis-specific DR 
region were then designed [79]. The primers bound to a 38-bp-long sequence present in 
the 4392-bp-long DR region [80]. The DR is a highly constant target region repeated 42 
times in the MTB genome between 3119185 and 3123576 bp (Figure 3.13), thus in-
creasing the chance of detecting MTB-specific DNA with a high sensitivity. The 5’-Cy5-
labelled forward primer had a length of 17 bp. Its reverse complementary primer was 15 
bp in length and was BHQ-labelled at its 3’ end. The defined reverse primer had a 
length of 18 bp. The amplified PCR product was 38 bp in total length. 
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(source: NCBI Ref sequence NC_000962.3) 
Figure 3.13: Direct repeat (DR) region located in the Mycobacterium tuberculosis 
genome. This DR region is 4392 bp in length. 
 
3.11.3 PCR reaction mix for detection of MTB-specific Tr-DNA using DR target 
The PCR reaction buffer consisted of potassium chloride (KCL) 250 mM, tris-sulfate 375 
mM (pH 8.5), EDTA 50 µM, magnesium chloride (MgCl2) 15 mM, Tween-20 1.25%, tre-
halose 1 M and sodium azide 0.225%. The PCR master mix was prepared by 
combining molecular grade water, reaction buffer, dNTP mix (containing dATP, dGTP, 
dCTP, and dTTP), forward primer, reverse primer, quencher, forward primer–IPC, 
reverse primer–PC, reporter–IPC, reporter–positive hybridization control, and Taq 
polymerase (Life Technologies, USA). The Table 3.4 shows the final concentration of 
the master mix reagents. Fresh master mix solution was prepared daily in a master mix 
room, and an isolated DNA eluate was added in a separate room. 
 
Table 3.4: Reaction mix required for PCR targeting the DR region  
Substances Final concentration 
Molecular grade water 48.30 µl 
PCR reaction buffer 20.00 µl 
dNTP mix 0.2 mM 
Forward primer: Cy5 0.3 µM 
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Substances Final concentration 
Reverse primer 0.3 µM 
Quencher: BHQ 0.3 µM 
Forward primer: IPC 0.3 µM 
Reverse primer: IPC 0.3 µM 
Reporter: IPC 0.010 µM 
Reporter: positive hybridisation control 0.010 µM 
Taq 0.250 U/µl 
DNA IPC pEX-A-template_320_321_200 10,000 copies/reaction 
Final volume 100   µl 
 
The double-stranded primer-based PCR protocol was implemented using the Alere q 
analyser, and run using on-board assay software. For the PCR reaction, 10 µl of isolat-
ed DNA eluate was added to 90 µl of freshly-prepared master mix solution. Each DNA 
eluate was measured in triplicates to determine the reproducibility and reliability of the 
assay. In cases of failure, the test was repeated until three valid results were achieved. 
The mean Ct-value was taken into consideration for the final TB diagnosis. Different 
sets of Ct-values for daily analyser quality control (negative and positive control), inter-
nal process control (positive and negative) and sample were recorded. To determine the 
test positivity rate, a capture calibration curve was made spanning a concentration 
range from 1 to 10,000 copies of H37Rv gDNA per test. Based on the lowest measura-
ble concentration, a cut-off was defined to determine the threshold for defining positives 
and negatives. 
 
3.12 Quantification of Tr-DNA using IS6110 and DR target amplification  
The capture and amplification efficiencies for the MTB-specific IS6110 and DR region 
were determined using the Tr-DNA-based PCR assay. The urine samples were spiked 
with serial dilutions of gDNA from the MTB-reference strain H37Rv. Different 
concentrations of gDNA from the MTB reference strain H37Rv ranging from 1 cp to 
10,000 cp. For estimation of DNA capture efficiency, H37Rv was spiked into the urine 
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and isolated using the in-house method. Furthermore, for estimation of PCR amplifica-
tion efficiency the H37Rv gDNA was directly spiked in to the master mix solution. The 
calibration curves for IS6110 were generated on the AB cycler and for the DR region on 
the Alere q analyser. The calibration curves for the DR region were generated using the 
22-min two-step PCR protocol. All experiments were run in triplicates and the mean Ct-
values were plotted vs. the concentration of log H37Rv gDNA. 
 
3.13 Controls and precautions to prevent contamination 
Contamination of the reagents and lab facility can negatively impact assay quality. Thus, 
in addition to negative isolation controls, PCR reagents including the target-specific pri-
mers must be contamination free. Therefore, differing sets of isolation (extraction), ana-
lyser and internal process controls were implemented in the Tr-DNA assay. The internal 
process controls included an artificial sequence cloned into the plasmid pEX-A vector 
(Eurofins Scientific, Germany). These checks aided in observing the reagent quality 
(cross contamination and stability), the performance of the isolation method and Alere q 
analyser. For DNA isolation, a negative control (normal urine) and positive control 
(normal urine spiked with H37Rv genome) were isolated in duplicates during the first 
and last round of isolation. All Alere q analysers were tested running a negative control 
(molecular grade water) and a positive control (H37Rv genome) in the cartridge daily to 
monitor analyser performance. The Alere q analysers were inspected for any perfor-
mance deviation and were sent immediately to technical service if this was detected.  
Furthermore, to avoid cross contamination through reagents, all good laboratory prac-
tices were taken into consideration, i.e., separating master mix and template handling 
area. All biosafety cabinets (BSC) were run with the appropriate air circulation and disin-
fected using DNA-Exitus (VWR Darmstadt, Germany) before and after pipetting. Cali-
brated pipettes and single-use dual filter pipette tips (PCR clean/sterile) were used. All 
stock solutions were aliquoted into smaller volumes and stored at the appropriate tem-
perature. 
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3.14 Statistical analysis 
A database was created using Microsoft Excel 2010 (Microsoft Inc. Redmond, USA). 
Data quality control was performed on a regular basis, including the raw data collected 
from participants’ case reporting forms (CRFs). Results from urine dipstick testing and 
PCR data were stored in a separate Excel sheet. Bar charts were created using Excel. 
The study cohort was characterised with descriptive statistics for various demographic 
data and clinical symptoms. Different sets of statistical tests (chi-square, Kruskal-Wallis 
one-way analysis of variance, and logistic regression) were performed using Sigma Plot, 
version 11 (Systat Software GmbH, Erkrath, Germany). The sensitivity (true posi-
tive/total positive), specificity (true negative/total negative), negative predictive value 
(true negative/{true negative + false negative}), positive predictive value (true posi-
tive/{true positive+ false positive}), negative likelihood ratio ({100 – sensitivi-
ty}/specificity), and positive likelihood ratio (sensitivity/{100 – specificity}) were 
calculated the for Tr-DNA assay, using the liquid culture as the reference method [81]. 
The two groups were compared using a Man-Whitney Rank sum test or t-test (two-sided) 
at an alpha of 0.05, and 95% CIs were calculated using the exact Clopper-Pearson, log 
method and standard logit model. The Z tests for proportions were performed for sex, 
HIV status and TB history. Receiver operating characteristic (ROC) curves were 
generated to show sensitivity and specificity against different diagnostic tests (sputum 
smear microscopy, Xpert MTB/RIF and liquid culture) [82]. ROC curves were also gen-
erated to compare assay performance for IS6110 and DR targets. The Fisher exact Chi-
square test was performed to check the statistical difference between male and female 
regarding HIV prevalence. The multivariate and univariate analyses for potential 
confounding variables and odds ratios (ORs) was calculated by logistic regression. A 
Venn four-set diagram using ellipses was generated, showing the relationships between 
the different diagnostic tests.  
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4 Results 
4.1 Optimisation of the in-house developed Tr-DNA isolation method 
4.1.1 Result of synthetic DNA fragment and H37Rv analyses 
The in-house developed Tr-DNA isolation method was developed and optimised using 
synthetic DNA fragments of different lengths (38 bp, 50 bp, 75 bp, 150 bp, and 200 bp) 
and H37Rv gDNA. The mean Ct-values from three runs for all PCR experiments and 
the percentage of PCR efficiency are given in Table 4.1. PCR efficiencies were higher 
for smaller DNA fragments (38bp, 50 bp, and 75 bp), and the H37Rv gDNA showed 
values close to 100% compared to the 150 bp and 200 bp DNA fragments with values 
of 81.39% and 90.27%, respectively. The overall excellent performance of DNA frag-
ment amplification indicated process stability and reagent functionality. All PCR nega-
tive controls gave, as expected, an undetected result. The limit of detection was 
determined to be 100 copies for all DNA fragments, and the Ct-values were found to be 
consistent from a concentration of 100 cp to the highest concentration; this was con-
firmed by a two-to-three Ct-value decrease for each log step. 
 
Table 4.1: Cycle threshold and percentage of PCR efficiency for DNA fragments 
and H37Rv gDNA  
DNA 
length 
Negative 
control 
Mean Ct-value (DNA concentration) % PCR 
efficiency 10 cp 10
2 
cp 10
3 
cp 10
4
 cp 10
5 
cp 10
6 
cp 10
7 
cp 
38 bp 39.76 37.52 35.72 32.16 28.87 25.49 21.90 18.35 101.79 
50 bp Undetected* 36.50 33.13 29.64 26.24 22.76 19.40 16.45 97.85 
75 bp Undetected* 34.81 31.78 28.68 25.17 21.90 18.64 N/A 102.84 
150 bp 39.29 N/A 36.62 33.17 29.77 24.86 21.44 N/A 81.39 
200 bp 38.25 N/A 35.94 32.55 N/A 25.24 21.57 18.20 90.27 
H37rv 
gDNA 
Undetected* 32.24 28.70 25.37 22.19 18.87 N/A N/A 99.83 
 
 
*Undetected: Ct-value ≥ 40; N/A: Not applicable (not performed) 
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An amplification curve over the measured concentration range is shown for the 38-bp 
DNA fragment in Figure 4.1. The calibration curves for all DNA fragments and for the 
H37Rv genome showed a very high coefficient of determination (R2) ≥ 0.995 (Figure 
4.2). However, the determined Ct-values were not comparable between the different 
DNA fragments, and were generally higher than the same concentration of H37Rv 
gDNA. These results reflect the number of available IS6110 repeats in the H37Rv ge-
nome, namely 16 instances in H37Rv compared to one repeat in the synthetic DNA 
fragments (Appendix 2). Furthermore, H37Rv is more stable than the DNA fragments in 
solution, which may also have impacted PCR performance.  
 
 
Figure 4.1: PCR amplification shown for the 38-bp DNA fragment for serial dilu-
tions from 10 to 107  
The thick black line indicates the cut-off value of 50,000 RFU. 
 
102 103 104 105 106 107 10
 Cut-off at 50,000 RFU 
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Figure 4.2: Calibration curves for various lengths of DNA fragments and H37Rv 
gDNA using serial dilution up to 7 log copies 
 
4.1.2 Optimisation of urine and reagent volumes 
Different volumes of urine (4.0, 2.0, 1.0 and 0.5 ml) were tested in triplicates. The 
correct ratio of urine volume to capture the matrix and binding buffer were evaluated 
using 2500 copies of the 50-bp DNA fragment. Among all tested combinations, no 
significant differences were found for varying urine volumes (p = 0.114; Figure 4.3). 
Using the largest urine volume (4 ml) also increased the chance of capturing the 
relatively sparse MTB-specific DNA fragments present in the sample. 
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Figure 4.3: Optimisation of urine and reagent volume for the in-house developed 
method  
The vertical lines show the 95% CI and black dot shows the mean cycle threshold (Ct) value for sample 
measured in triplicates 
 
4.1.3 DNA content measurement for urine samples  
Tr-DNA was extracted from five different urine samples using both the in-house and 
Qiagen methods. The DNA content of eluate was measured using the PicoGreen meth-
od and summarised in Table 4.2. The total DNA yield was higher for the in-house 
method than the Qiagen method (p = 0.002). The DNA yield varied from 190 – 3006 
ng/ml for the in-house method and from 6.3 – 434 ng/ml for the Qiagen method. These 
results indicate that the capture matrix used in the in-house method is capable of isolat-
ing high amounts of DNA, which may increase the chances of detecting the low concen-
trations of the target in urine.  
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Table 4.2: Overview of mean DNA concentration (ng/ml) for the in-house and Qi-
agen methods, measured using the PicoGreen approach. 
DNA fragment 
length (bp) 
In-house method Qiagen method 
Mean DNA 
content (ng/ml) 
Mean DNA 
content (ng/ml) 
38 933 6.3 
50 3006 42 
75 292 21 
100 384 36 
150 282 22 
200 190 7.6 
H37Rv gDNA N/A 434 
N/A: Not applicable (not performed) 
 
4.1.4 DNA recovery from spiked urine samples 
Yield percentages were calculated based on DNA fragment-specific calibration curves 
generated using pure DNA fragments. Figure 4.4 shows the mean DNA recovery (%) for 
both the in-house and Qiagen methods. For the Qiagen method, the yield percentage 
increased with the DNA fragment length, from 22.9% (38 bp) to 68.8% (150 bp), and 
decreased to 32.3% for the 200 bp DNA fragment. For the in-house method, the yield 
varied from 19.7% (38 bp) to 27.3% (75 bp), and declined to 16.3% for the 100-bp size 
and longer. The 200-bp fragment showed the lowest level of DNA recovery (190 ng/ml), 
and a yield of 3.9%. For the Qiagen method, the 38-bp fragment showed the minimum 
level of total DNA content (6.3 ng/ml) and had a yield of 22.9%. H37Rv gDNA recovery 
was 37.8% and 49.3% for the in-house and Qiagen methods, respectively. Overall, the 
Qiagen method showed a higher yield percentage compared to the in-house method (p 
= 0.001).  
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Figure 4.4: Percentage of recovery from spiked urine samples for the in-house 
and Qiagen methods for DNA fragments and H37Rv gDNA, measured in triplicate  
 
4.1.5 Purity of PCR products 
The purity of the PCR products amplified from the DNA fragments (38 bp, 150 bp, and 
200 bp) was confirmed using gel electrophoresis. Figure 4.5 shows the specific bands 
observed for all analysed DNA fragments. Gel electrophoresis showed a very clear 
separation for different DNA fragments (38 bp, 150 bp, and 200 bp). Furthermore, no 
unwanted side products were observed, confirming the specificity of target-specific am-
plification.  
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Figure 4.5: Gel electrophoresis bands for the 38-bp, 150-bp, and 200-bp DNA 
fragments. Size ladders are included in the first and last positions 
 
4.1.6 Evaluation of PCR efficiency 
PCR performance data from isolated DNA fragments of different lengths (38 bp, 50 bp, 
75 bp, 100 bp, 150 bp, 200 bp, and H37Rv genome) were used as mean delta Ct-
values, which were reproducible for both methods (Figure 4.6). Overall, the average 
delta Ct-values were found to be higher for the in-house method than for the Qiagen 
method. The standard deviation (SD) values for the in-house method were in the range 
of 0.09 – 1.36 and for the Qiagen method 0.08 – 1.65. For the in-house method, the 
lowest value (0.09) was observed for the 150 bp fragment, and the highest value (1.36) 
for the 200 bp fragment. For the Qiagen method, the minimum value (0.08) was ob-
served for both the 38-bp fragment and H37Rv, and the highest value (1.65) for the 
200-bp fragment. The SD value between the two isolation methods showed no differ-
ence (p = 1.00). The effect of PCR inhibition was the lowest for the amplification of the 
50-bp fragment and H37Rv gDNA, and the highest for the 150 bp fragment using in-
house method. The Qiagen method showed a low level of inhibition for all processed 
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DNA fragments. For the 150-bp fragment, a negative delta Ct-value was measured. A 
negative value indicates that the Ct-value of the eluate was lower than that of the posi-
tive control. The minimum impact on PCR efficiency was observed for the H37Rv gDNA, 
which reached equal mean delta Ct-values.  
 
 
Figure 4.6: Influence of inhibitors on delta cycle threshold (Ct) value for the in-
house and Qiagen methods, measured with DNA fragments and H37Rv gDNA 
 
4.1.7 Influence of urine sample on PCR efficiency 
The degrees of inhibition among different urine samples were determined using the 
DNA fragments (38 bp, 50 bp, 75 bp, 100 bp, 150 bp, 200 bp) and H37Rv gDNA. The 
Ct-values from the different DNA fragment lengths were combined according to the 
urine number, and the corresponding delta Ct-values were calculated. The mean delta 
Ct-values (difference between eluate control and inhibition control) for the six different 
urine samples are shown in Figure 4.7. Clearly, urine sample 9 carried less inhibitors 
compared to urine sample 7, as indicated by the lowest and highest delta Ct values, 
respectively. In contrast to in-house method, the Qiagen method showed almost no in-
hibition. The data show that the urine samples were heterogeneous, carrying different 
amounts of inhibitory components. The ability of the isolation method to remove inhibi-
tors was therefore affected by the urine samples.  
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Figure 4.7: Effect of different urine samples on PCR efficiency, shown as delta 
cycle threshold value for the Qiagen and in-house methods  
Difference sets of DNA fragments and H37Rv gDNA was spiked in each urine samples from 4 to 9, and 
mean delta Ct-value was calculated for urine. 
 
4.1.8 Effect of eluate volume on PCR efficiency 
Three different, tested eluate volumes (10 µl, 20 µl, and 40 µl) from three urine samples, 
together with their mean delta Ct-values, are shown in Figure 4.8. The DNA contents for 
urine A, B, and C were 399 ng/ml, 280 ng/ml, and 535 ng/ml, respectively. 10 µl of 
eluate volume showed the lowest delta Ct-values for all three urine samples indicating, 
less or no PCR inhibition. Increasing the eluate volume to 20 µl further increased the 
PCR inhibition, which was reflected in the higher delta Ct-values observed: up to 0.83 
compared to 0.22 using the 10 µl eluate. Complete PCR inhibition was observed with 40 
µl of eluate volume. Overall, the degree of PCR inhibition was directly associated with 
the eluate amount and urine DNA concentration. Urine B had the lowest level of DNA 
content and accordingly showed the lowest inhibition.  
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Figure 4.8: Effect of different eluate volumes on PCR efficiency, isolated using the 
in-house method, shown for three different urine samples  
For the 40 µl eluate volume, complete PCR inhibition was observed and a delta Ct-value of 11 was 
attained. 
 
4.1.9 Effect of eluate dilution on PCR efficiency 
The effect of eluate dilution on processed urine samples is shown in Figure 4.9 as mean 
Ct-values (duplicate measurements). All five urine samples showed reproducible results 
for all eluate dilution series derived from both isolations. The lowest Ct-value was 
measured for 1:2 dilutions, which differed statistically from undiluted samples (p < 
0.001). This result further confirmed the presence of PCR inhibitors, as Ct-value was 
lower for the 1:2 dilution than that observed for the undiluted sample. From the 1:4 dilu-
tions onwards, an increase in Ct-value was observed, representing the decreasing tar-
get concentration. This data suggest that 10 µl may be the optimal eluate volume. All 
negative controls were undetected (Ct-value ≥ 40). 
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Figure 4.9: Effect of different eluate dilution series on PCR efficiency, isolated 
using the in-house method and measured for five different urine samples  
The eluate was diluted in series, commencing from 1:2 increasing to 1:16 using molecular grade water. 
 
4.1.10 Performance comparison of two Tr-DNA isolation method using clinical samples 
The in-house developed method was optimised using a model system based on control 
urine samples spiked with DNA fragments or H37Rv gDNA. Furthermore, the capabili-
ties of the in-house and Qiagen isolation methods to enrich MTB-specific Tr-DNA from 
urine were evaluated using clinical samples. Both tested samples were liquid culture 
positive on MGIT. Tr-DNA was isolated from 4 ml of urine and concentrated in 50 µl 
eluate; 20 µl of eluate was then added to 80 µl of master mix. Each eluate and the isola-
tion (extraction) controls (negative and positive) were isolated and measured in dupli-
cates. The positive controls for the in-house and Qiagen method were 34.88 and 38.04, 
respectively (Figure 4.10). The negative control was undetectable (Ct-value ≥ 40) for 
eluate isolated using both methods. Both methods were able to isolate the MTB-specific 
Tr-DNA. However, the optimised in-house method showed lower Ct-values for both 
patient samples as for positive control than those found with the Qiagen method. In 
summary, preliminary data using clinical samples confirmed the potential of developed 
in-house method for isolating MTB-specific Tr-DNA from urine.  
 
31
31.5
32
32.5
33
33.5
34
34.5
35
No Dilution Dilution 1:2 Dilution 1:4 Dilution 1:8 Dilution 1:16
c
t-
v
a
lu
e
 (
m
e
a
n
) 
Urine 1
Urine 2
Urine 3
Urine 4
Urine 5
62 
 
 
Figure 4.10: Performance comparison between the Qiagen and optimised in-
house isolation methods using clinical samples  
As a positive control, H37Rv gDNA in a concentration of 100 copies was used. The positive control was 
spiked in healthy urine and DNA was isolated using both methods.  
 
4.2 Study cohort demographic characteristics  
In total, 428 adult pulmonary TB suspects were enrolled between July and November, 
2013, at three clinical sites in Langa (n = 162), Gugulethu (n = 209) and Vanguard (n = 
57) in Cape Town, South Africa. The baseline demographics and clinical characteristics 
of the study cohort are presented in Table 4.3. Study participants had a male: female 
ratio of 1.5:1. The median age of participants was 39 years (range: 19-80 years, inter-
quartile range (IQR): 29.96 – 49.16). HIV prevalence was higher among men than 
women (p < 0.001). The CD4 T lymphocyte median cell count was 249 cells/mm3 (range 
8 – 798 cells/mm3, IQR: 148 – 390 cells/mm3). Median BMI was 22.13 kg/m2, with an 
IQR of 19.43 – 25.30.  
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Table 4.3: Study participant characteristics (demographic and clinical) at enrol-
ment at three clinical sites in Cape Town, South Africa  
All demographic and clinical characteristics were recorded using the case reporting form.  
Study cohort characteristics (n = 426)* Number (percentage) 
Sex  
Male 256 (60.09) 
Female 170 (39.91) 
TB history  
No 262 (61.50) 
Yes 164 (38.50) 
- TB therapy completed 146 (89.02) 
- TB therapy not completed 18 (10.98) 
HIV Status  
Negative 264 (61.97) 
Positive 162 (45.07) 
ART: Yes 48 (29.63) 
ART: No 114 (70.37) 
CD4+ T cell count, cells/mm
3 
  
- ≤ 200  64 (39.50) 
- 201 – 350  49 (30.25) 
- > 350  49 (30.25) 
Diabetes mellitus  
No 413 (96.95) 
Yes 13 (3.05) 
Cough: Current  
No 8 (1.88) 
Yes 418 (98.12) 
Cough: Longer than 2 weeks  
No 48 (11.27) 
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Study cohort characteristics (n = 426)* Number (percentage) 
Yes 378 (88.73) 
Phlegm production  
No 14 (3.29) 
Yes 412 (96.71) 
Blood in sputum  
No 363 (85.21) 
Yes 63 (14.79) 
Weight loss  
No 75 (17.61) 
Yes 351 (82.39) 
Anorexia  
No 120 (28.17) 
Yes 306 (71.83) 
Night sweats  
No 83 (19.48) 
Yes 343 (80.52) 
Fatigue  
No 71 (16.67) 
Yes 355 (83.33) 
Shortness of breath  
No 203 (47.65) 
Yes 223 (52.35) 
Fever  
No 308 (72.30) 
Yes 118 (27.70) 
Chest pain  
No 82 (19.25) 
Yes 344 (80.75) 
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Study cohort characteristics (n = 426)* Number (percentage) 
BMI (kg/m
2
)  
< 18.5 (underweight) 64 (15.02) 
18.5 – 24.9 (normal range) 250 (58.69) 
25.0 – 29.9 (overweight) 66 (15.49) 
> 30.00 (obese) 46 (10.80) 
*From 428 enrolled patients, two were excluded due to urine sample unavailability. ART: Antiretroviral therapy. BMI 
classified according to WHO criteria. 
 
4.3 Laboratory testing for TB diagnosis 
From 428 enrolled TB suspects, two patients were excluded from the study due to lack 
of an available urine sample. The liquid MGIT culture, Xpert MTB/RIF, and smear mi-
croscopy tests performed on 413 (96.95%), 425 (99.77%), and 424 (99.53%) sputum 
samples, respectively. Patients were classified as TB positive based on liquid culture 
and Xpert MTB/Rif test results. However, liquid culture was not performed on 15 sam-
ples; here, TB diagnosis was made based on Xpert MTB/RIF test results. One sputum 
sample was found to be contaminated, and on repeated testing of the reserved sample, 
the test returned a negative result. Positive TB status was related to HIV infection (p < 
0.001) and was not related to patient sex (p < 0.857).  
Figure 4.11, below, shows the flow diagram for the routine TB diagnoses performed in 
Cape Town. Median time to culture positivity was 16 days (IQR: 13 – 21 days). One pa-
tient tested positive for rifampicin mono-resistance (0.57%), and 3 patients (1.71%) 
tested positive for multi-drug resistance to rifampicin and isoniazid. Among the Xpert 
MTB/RIF positive results, six (3.08%) patients were rifampicin resistance. The median 
days to culture positivity among the negative smear group was 21 days, and 15 days for 
the smear positive group (p < 0.001). 
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Figure 4.11: Flow diagram showing TB diagnosis using sputum-based tests, liq-
uid MGIT culture, Xpert MTB/RIF molecular test, and smear microscopy 
*One liquid culture sample was found to be contaminated, and retesting was performed using reserve 
sputum. For liquid culture, sputum was incubated at 37°C for up to 42 days (6 weeks), and positive sam-
ples underwent further drug susceptibility testing using the MTBDR plus line probe assay (Hain Lifesci-
ence, Nehren, Germany). Smear microscopy results was graded from scanty to 3+. All sputum-based 
tests were performed by the NHLS lab in Cape Town, South Africa.  
 
4.4 Characterisation of urine sample  
All urine samples underwent Combur testing and visual control for colour. Most samples 
were pale straw yellow or transparent yellow. The results of Combur test parameters 
such as specific gravity, pH, the presence of leukocytes and erythrocytes, and protein 
score are presented for TB positive and negative samples (Figure 4.12). Specific gravity, 
428 pulmonary TB suspects enrolled 
Liquid Culture* 
n= 413 (96.95%) 
Positive  
n=175 (42.37%) 
Rifampicin Suseptible 
n=65 (37.14%) 
Rifampicin Resistance 
n=4 (2.29%) 
Isoniazid Suseptible 
n=64 (36.57%) 
Isoniazid Resistance 
n=5 (2.86%) 
Negative 
n=238 (57.63%) 
Xpert MTB/RIF 
n= 425 (99.77%) 
Positive 
n=195 (45.88%) 
Rifampicin Suseptible 
n=186 (95.38%) 
Rifampicin Resistance 
n=6 (3.08%) 
Inconclusive 
n=3 (1.54%) 
Negative 
n=230 (54.12%) 
Smear Microscopy 
n= 424 (99.53%) 
Positive 
n=138 (32.55%) 
scanty 
n=41 (29.71%) 
1+ 
n=40 (28.99%) 
2+ 
n=21 (15.22%) 
3+ 
n=35 (25.36%) 
Negative 
n=286 (67.45%) 
Excluded 
2 suspects: no urine sample available 
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pH, and the presence of leukocytes and erythrocytes were not dependent on patient TB 
status (p > 0.05). However, the protein score was found to be associated with TB status 
(p = 0.015). 
 
 
 
Figure 4.12: Urine sample characterization through visual control and Combur 
testing.  
Sub-figures A-F represents different parameter measures, such as colour (A), specific gravity (B), pH (C), 
protein score (D), leukocytes (E) erythrocyte (F). 
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4.5 Implementation and optimisation of PCR method using Alere q 
A series of experiments were performed to implement and optimise the DSP-based 
PCR method using the Alere q. Initially, six different PCR protocols, including variants of 
a short two and a conservative three-step PCR protocol were analysed for performance 
(Table 4.4 and Figure 4.13).  
 
Table 4.4: An overview of double-stranded primer-based PCR optimisation using 
the automated molecular analyser Alere q.  
 
 
# 
Initial 
denaturation 
Annealing Elongation Denaturation 
Cycle 
# 
Ct 
value 
(mean) 
Ct 
value 
(SD) 
Assay 
time 
(min) 
 
1 95°C 
60 sec 
60°C 
10 sec 
72°C 
5 sec 
95°C 
5 sec 
45 33.94 0.11 25 
2 95°C 
60 sec 
60°C 
20 sec 
70°C 
5 sec 
95°C 
5 sec 
40 31.56 0.26 33 
3 95°C 
60 sec 
60°C 
20 sec 
72°C 
5 sec 
95°C 
5 sec 
45 31.71 0.13 30 
4 95°C 
60 sec 
60°C 
20 sec 
N/A 
95°C 
5 sec 
40 31.75 0.23 22 
5 95°C 
60 sec 
60°C 
25 sec 
N/A 
95°C 
5 sec 
40 31.36 0.64 27 
6 95°C 
60 sec 
60°C 
35 sec 
N/A 
95°C 
5 sec 
40 32.06 0.01 32 
NB: Six different variations were tested for PCR optimisation. N/S Not applicable (not performed), Sec= 
seconds 
 
In the two-step PCR method, annealing and elongation were performed simultaneously 
at a temperature of 60°C. The two tested annealing phase (20 sec vs. 10 sec) shows no 
difference in performance (p = 0.07). Overall, the three-step PCR showed a broader 
range of values, varying from 31.71-33.94, compared to the two-step PCR (31.36 – 
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32.06). Furthermore, attempts to optimise the performance by increasing the elongation 
temperature of the three-step protocol to 72°C and increasing the total number of PCR 
cycles (45 vs 40) were unsuccessful. Overall, the total time required for the PCR proto-
cols was between 22 and 33 min for all six variants. The lowest PCR analysis time (22 
min) was obtained with the two-step PCR protocol (annealing and elongation at 60°C for 
20 sec). No significant difference between the six variants was observed (p > 0.05). The 
SDs of the mean Ct values were in the range of 0.01 – 0.64. To reduce the time to re-
sults, the shorter two-step PCR protocol was chosen and integrated into the Alere q as-
say software.  
In addition to the PCR protocol, the primer: quencher (P: Q) ratio is also a critical pa-
rameter regarding the performance of the DSP-based PCR. We evaluated different P: Q 
ratios using H37Rv gDNA in triplicates. Table 4.5 shows the PCR data for the P: Q op-
timisation. A P: Q ratio of 1:1 showed the lowest Ct (33.89) and SD (0.27) values com-
pared to the other ratios tested. The negative controls were undetected for all three 
tested ratios.  
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Figure 4.13: Double-stranded primer-based PCR optimisation overview using 
Alere q. Six different variations were tested for various PCR settings.  
The cut-off was defined at a fluorescence signal intensity of 0.1. 
 
Table 4.5: Primer: Quencher (P: Q) ratio optimisation for double-stranded primer-
based PCR using H37Rv gDNA in Alere q 
Sample Primer:Quencher ratio Ct value (mean)
#
 SD 
Negative control 
1.0:1.0 Undetected* N/A 
1.0:1.5 Undetected* N/A 
1.0:2.0 Undetected* N/A 
H37Rv gDNA 100 
copies 
1.0:1.0 33.89 0.27 
1.0:1.5 33.95 1.42 
1.0:2.0 34.91 1.35 
#
Mean Ct value of three measurements. *Undetected: ≥ 40 Ct value. SD: standard deviation. N/A: not applicable. 
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4.6 Detection of Internal Process Control 
The specificity of the IPC product was examined using melt curve analysis. This was 
performed using the standard PCR protocol specific to IS6110 on an AB cycler. Figure 
4.14 shows melt curves for both MTB-specific amplicon and IPC, which yielded clearly 
separated melting temperatures (Tm values). The Tm for the sample and the IPC were 
74.5°C and 81.0°C, respectively. 
 
 
Figure 4.14: Melt curve analysis for the internal process control and MTB-specific 
target (IS6110),  
Experiments were performed on an AB cycler in triplicates, shows the different melting temperatures for 
both PCR products. The red vertical line shows a Tm of 74.5°C for the target sample; the blue vertical line 
shows a Tm of 81.0°C for the IPC. 
4.7 Calibration curve for target amplification using IS6110 and DR  
For the calbration curve, all experiments were run in triplicates and the mean Ct-values 
were plotted vs the concentration of log H37Rv gDNA (Figure 4.15). The results showed 
that calibration curves for pure spiked DNA (DNA calibration curve) and DNA isolated 
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using the in-house method (capture calibration curve) were linear over the complete 
measured range, from log 0 to log 4 H37Rv gDNA for both target regions (IS6110 and 
DR). For the IS6110 region, PCR and capture calibration curve showed PCR efficien-
cies of 94.5% and 104.0% respectively. For the DR region, the PCR and capture cali-
bration curve showed PCR efficiencies of 108% and 104% respectively. A R2 value of > 
0.990 was achieved for all calibration curves. The limit of detection was determined to 
be five H37Rv gDNA using PCR and a capture calibration curve. 
 
Figure 4.15: Performance characteristics of capture and amplification efficiency 
for the MTB-specific targets IS6110 and DR.  
Serial diluted H37Rv gDNA were tested in triplicates, and the mean Ct-values were plotted against the log copy. 
4.8 DNA isolation and quantification from clinical samples 
The first 100 samples (50 positive liquid cultures and 50 negative liquid cultures) were 
isolated in duplicates, and total DNA content was measured using the PicoGreen meth-
od. The controls (negative and positive) were included in isolation process to monitor 
the reagent quality and presence of cross contamination. Each eluate was measured in 
duplicates, and mean concentration values were shown using box plots (Figure 4.16). 
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The measured mean DNA content (ng/ml) of female participants (n = 35) was higher 
than that of male participants (n= 65; p < 0.001). TB-positive participants had a higher 
DNA content than TB-negative participants (p = 0.020).  
 
 
Figure 4.16: DNA content (ng/ml) measured using the PicoGreen method, divided 
into sex and TB status for the 50 negative and 50 positive liquid culture urine 
samples.  
 
4.9 Performance comparison of IS6110 and DR target using clinical 
samples 
The sensitivity and specificity of the MTB-specific targets, IS6110 and DR were com-
pared using data generated on an AB cycler and Alere q analyser. The IS6110-based 
PCR method was performed on an AB cycler using SYBR Green [70]. The DR-based 
PCR method was conducted in the Alere q analyser using the DSP-based protocol. Fifty 
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positive and 50 negative liquid culture urine samples were isolated in duplicates, yield-
ing a final eluate volume of 75 µl using the Tr-DNA extraction method. Each eluate was 
tested in duplicates using both PCR protocols. In total, four measurements were rec-
orded. For the IS6110 a target sensitivity of 50% (95% CI: 35.53 – 64.47) and specificity 
of 96.23% (95% CI: 87.02 – 99.57), and for the DR region a target sensitivity of 54% (95% 
CI: 39.32 – 68.19) and specificity of 98.11% (95% CI: 89.93 – 99.95) were determined. 
The receiver operating characteristic (ROC) curves for both targets are shown in Figure 
4.17. Employing the DR target, a higher sensitivity and specificity were reached than 
when using the IS6110 target.  
 
 
Figure 4.17: Receiver operating characteristic (ROC) curve comparison for the 
MTB-specific targets IS6110 (black line) and direct repeat (DR) region (red line).  
The area under the curve for the IS6110 and DR region were 0.80 and 0.89, respectively. 
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4.10 Evaluation of cross-contamination 
Reagent purity was confirmed by gel electrophoresis for the IS6110 and DR regions. In 
total, 10 different reagent combinations were tested for contamination and specificity 
(Figure 4.18). No unspecific side product bands were detected on the gel.  
 
Figure 4.18: Evaluation of reagent purity for cross contamination using gel elec-
trophoresis. 
 
Furthermore, contamination control was performed, namely a 1.5-ml tube containing 
PBS buffer, was left open to monitor for lab contamination. Normal control urine (con-
taining no spiked DNA fragments) was used as a negative control, and spiked urine 
containing 3500 H37Rv gDNA was designated the positive control. Table 4.6 shows the 
mean Ct-values obtained for the experiments performed. Contamination control was 
found to be negative in all experiments.  
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Table 4.6: An overview of the experiments performed for reagent purity and cross 
contamination for IS6110 and DR region targets 
 
Real-time RT-PCR analyser Alere q* 
Sample Ct-value IS6110 Ct-value DR Ct-value DR 
Negative control 40.00 40.00 40.00 
Positive control 33.06 32.04 31.81 
Contamination control 40.00 40.00 40.00 
* Only the DR region was measured using the Alere q. 
 
4.11 Evaluation of Alere q analyser performance 
In total twelve analysers were used for the Tr-DNA eluate analysis. Daily QC, using 100 
copies of H37Rv gDNA, was performed for each Alere q analyser used for the study. A 
run chart in the form of Levey-Jennings graph with ±3 SD is shown below (Figure 4.19). 
No significant differences among the 12 Alere q analysers (p = 0.728) were found.  
 
Figure 4.19: Levey-Jennings chart showing the daily performance of the Alere q 
analysers, measured using 100 H37Rv gDNA.  
The dashed red line shows the upper and lower control limits for ±3 SD; the black line shows the mean 
Ct-values measured,  
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4.12 Risk factors for Tr-DNA positive test results in clinical samples 
Risk factors for Tr-DNA positive test results were evaluated using the univariate and 
multivariate analysis logistic regression (Table 4.7). The association between patient 
characteristics (demographics and TB symptoms) and risk (odds ratio) of a positive Tr-
DNA test was determined as crude and adjusted odds ratios. Among all tested risk 
factors, only weight loss was a significant independent predictor of a Tr-DNA positive 
test, whereas all other parameters were not significant.  
 
Table 4.7: Univariate and multivariate logistic regression analysis showing the 
association between patient characteristics (demographic and clinical) and risk of 
a positive Tr-DNA test 
 
Crude 
odds ratio 
95% CI P value 
Adjusted 
odds ratio 
95% CI P value 
Sex       
Female 1.0 - - 1.0 - - 
Male 0.867 0.551-1.365 0.538 0.992 0.605-1.624 0.973 
HIV status       
HIV negative 1.0 - - 1.0 - - 
HIV positive 1.485 0.944-2.336 0.087 1.452 0.896-2.351 0.13 
TB history       
No 1.0 - - 1.0 - - 
Yes 0.839 0.528-1.336 0.460 0.803 0.497-1.3 0.373 
Current cough       
No 1.0 - - 1.0 - - 
Yes 1.899 0.226-15.96 0.555 1.891 0.191-18.676 0.586 
Cough > two weeks       
No 1.0 - - 1.0 - - 
Yes 1.03 0.504-2.106 0.936 1.023 0.465-2.253 0.954 
Weight loss       
No 1.0 - - 1.0 - - 
Yes 2.214 1.09-4.496 0.028 2.258 1.084-4.702 0.03 
Night sweats       
No 1.0 - - 1.0 - - 
Yes 0.947 0.539-1.662 0.848 0.835 0.451-1.547 0.567 
Fatigue       
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Crude 
odds ratio 
95% CI P value 
Adjusted 
odds ratio 
95% CI P value 
No 1.0 - - 1.0 - - 
Yes 1.629 0.837-3.173 0.151 1.487 0.737-3.002 0.268 
Shortness of breath       
No 1.0 - - 1.0 - - 
Yes 1.233 0.786-1.933 0.362 1.201 0.75-1.923 0.445 
Fever       
No 1.0 - - 1.0 - - 
Yes 0.989 0.6-1.629 0.965 0.959 0.57-1.614 0.876 
Chest pain       
No 1.0 - - 1.0 - - 
Yes 0.927 0.528-1.63 0.794 0.892 0.488-1.63 0.709 
 
4.13 Sensitivity and specificity of Tr-DNA assay using DR target  
Initial experiments showed an increased sensitivity for the DR target compared to the 
IS6110 region. Therefore, the entire study cohort was analysed for the DR target region 
using an Alere q analyser. All samples were isolated using the in-house developed Tr-
DNA method. A flow diagram illustrating the Tr-DNA test cohort is shown in Figure 4.20. 
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Figure 4.20: Flow diagram showing TB diagnosis made using a urine-based rapid 
Tr-DNA test carried out on an Alere q analyser.  
The performance characteristic of the Tr-DNA assay was compared to the liquid culture among HIV-
infected and non-infected patients. *HIV status not available: n = 1. 
 
Tr-DNA assay showed an overall sensitivity and specificity of 42.86% (95%CI: 35.42 – 
50.54) and 88.61% (95%CI: 83.86 – 92.36), respectively, when compared with liquid 
culture. Sensitivity and specificity calculated for sex, HIV status, CD4 count, and clinical 
site are shown in Table 4.8. For HIV-positive participants, a sensitivity of 45.24% and a 
specificity of 89.04% were achieved. A low CD4 count (< 200 cells/mm3) did not show 
any influence on the sensitivity and the specificity of the Tr-DNA assay. Regarding the 
three clinical sites, the highest sensitivity for Tr-DNA was measured within the Gug-
ulethu cohort (50.68%) and the lowest Tr-DNA sensitivity (20.83) was found in the Van-
guard cohort. The specificity of the Tr-DNA test result between all of the sites ranged 
from 84.38 – 92.00%. However, Tr-DNA assay positivity was not dependent on clinical 
site (p = 0.494), CD4 count (p = 0.051) or BMI (p = 0.069). In addition, no difference in 
428 pulmonary TB suspects enrolled 
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Tr-DNA 
Positive 
n=38 
Xpert 
MTB/RIF 
Pos n=38 
SM Pos  
n=28 
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Pos  
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sensitivity was found regarding sex (p = 0.447), HIV status (p = 0.078) or TB history (p = 
0.459).  
 
Table 4.8: An overview of the sensitivity, specificity, PLR, NLR, disease 
prevalence, PPV and NPV for the Tr-DNA assay, calculated for sex, HIV status, 
CD4 count, and all three clinical sites. 
 
Sensitivity 
(95% CI)
*
 
Specificity 
(95% CI)
*
 
PLR 
(95% CI)
+
 
NLR 
(95% CI)
+
 
PPV 
(95% CI)
#
 
NPV 
(95% CI)
#
 
Overall 
Tr-DNA 
42.86% 
(35.42-
50.54%) 
88.61% 
(83.86-
92.36%) 
3.76 
(2.54-5.58) 
0.64 
(0.56-0.74) 
73.53% 
(65.19-
80.47%) 
67.74% 
(64.70-
70.64%) 
Sex 
Male 
 
41.12% 
(31.70-
51.05%) 
89.93% 
(83.68-
94.38%) 
4.08 
(2.36-7.05) 
0.65 
(0.55-0.77) 
75.86% 
(64.54-
84.44%) 
66.49% 
(62.65-
70.12%) 
Female 
 
45.59% 
(33.45-
58.12%) 
86.73% 
(78.38-
92.74%) 
3.44 
(1.95-6.07) 
0.63 
(0.50-0.79) 
70.45% 
(57.45-
80.81%) 
69.67% 
(64.58-
74.32%) 
HIV status 
Negative 
 
40.00% 
(29.81-
50.87%) 
88.41% 
(82.50-
92.88%) 
3.45 
(2.11-5.65) 
0.68 
(0.57-0.81) 
65.45% 
(53.65-
75.62%) 
72.86% 
(69.22-
76.23%) 
Positive 
 
45.24% 
(34.34-
56.48%) 
89.04% 
(79.54-
95.15%) 
4.13 
(2.06-8.27) 
0.62 
(0.50-0.76) 
82.61% 
(70.33-
90.49%) 
58.56% 
(53.38-
63.56%) 
CD4 count (cells/mm
3
) 
≤200 
 
50.00% 
(34.90-
65.10%) 
87.50% 
(61.65-
98.45%) 
4.00 
(1.06-15.10) 
0.57 
(0.41-0.81) 
92.00% 
(75.29-
97.75%) 
37.84% 
(30.16-
46.18%) 
201 – 36.84% 89.66% 3.56 0.70 70.00% 68.42% 
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Sensitivity 
(95% CI)
*
 
Specificity 
(95% CI)
*
 
PLR 
(95% CI)
+
 
NLR 
(95% CI)
+
 
PPV 
(95% CI)
#
 
NPV 
(95% CI)
#
 
350 
 
(16.29-
61.64%) 
(72.65-
97.81%) 
(1.05-12.09) (0.49-1.01) (40.73-
88.79%) 
(60.07-
75.73%) 
>350 
 
42.11% 
(20.25-
66.50%) 
89.29% 
(71.77-
97.73%) 
3.93 
(1.19-12.95) 
0.65 
(0.43-0.97) 
72.73% 
(44.74-
89.78%) 
69.44% 
(60.27-
77.30%) 
Clinical sites
+
 
Gug-
ulethu 
50.68% 
(38.72-
62.60%) 
87.69% 
(80.78-
92.80%) 
4.12 
(2.47-6.87) 
0.56 
(0.44-0.72) 
69.81% 
(58.10-
79.41%) 
76.00% 
(71.33-
80.12%) 
Langa 
42.31% 
(31.19-
54.02%) 
92% 
(83.40-
97.01%) 
5.29 
(2.35-11.89) 
0.63 
(0.51-0.77) 
84.62% 
(70.99-
92.52%) 
60.53% 
(55.63-
65.22%) 
Vanguard 
20.83% 
(7.13-
42.15%) 
84.38% 
(67.21-
94.72%) 
1.33 
(0.43-4.09) 
0.94 
(0.73-1.21) 
50.00% 
(24.58-
75.42%) 
58.70% 
(52.44-
64.68%) 
PLR: Positive likelihood ratio; NLR: Negative likelihood ratio; PPV: Positive predictive value; NPV: Negative predictive 
value 
*Confidence intervals for sensitivity and specificity are "exact" Clopper-Pearson confidence intervals 
+
Confidence intervals for likelihood ratios were calculated using the "Log method" 
#
Confidence intervals for the predictive values are the standard logit confidence intervals 
+Clinical sites are township clinics in Cape Town, South Africa 
 
The combination of the Tr-DNA test and the smear microscopy results showed an in-
crease in TB sensitivity of 83.82% compared to smear microscopy test results alone 
(sensitivity of 75.14%). Among HIV-positive patients, combining smear microscopy and 
Tr-DNA tests results showed an increased sensitivity, from 73.49% to 84.34%. The re-
ceiver operating characteristics (ROC) curve for the Tr-DNA assay against liquid culture, 
smear microscopy and Xpert MTB/RIF is depicted in Figure 4.21. A rather poor area 
under the curve (AUC) of 0.67 was observed for the Tr-DNA assay when compared to 
the liquid culture, smear microscopy and Xpert MTB/RIF AUCs.  
In total, 27 samples tested with the Tr-DNA assay showed discordant results when 
compared to the liquid culture results after 42 days of incubation. Six of the 21 Tr-DNA 
82 
 
positive/liquid culture negative samples were Xpert MTB/RIF positive, which increased 
the sensitivity to 46.28% and the specificity to 91.14%. The remaining patient urine 
samples (n = 21) that had discrepant results between the liquid culture and Tr-DNA as-
says were further investigated using the Xpert MTB/RIF procedure, as described previ-
ously [83]. Overall, only one of the 21 urine samples returned a positive result using 
Xpert MTB/RIF. A detailed analysis of the false positive results is listed in Table 4.9. 
Figure 4.22 shows a Venn diagram of all four assays (liquid culture, Xpert MTB/RIF, 
sputum smear microscopy, and Tr-DNA).  
 
Figure 4.21: Receiver operating characteristic (ROC) curve for Tr-DNA compared 
to smear microscopy (black line), Xpert MTB/RIF (red line) and liquid MGIT culture 
(green line).  
The area under the curve for all three ROC curves is 0.67. 
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Figure 4.22: Venn diagram showing the number of positive samples diagnosed by 
sputum smear microscopy (n = 138), Xpert MTB/RIF (n = 195), liquid MGIT culture 
(n = 175) and Tr-DNA test (n = 102)  
In total, 58 patients were diagnosed as positive by all four tests; 21 patients were diagnosed as positive by the Tr-
DNA assay alone.  
 
 
Table 4.9: Xpert MTB/RIF test performed for discordant urine samples that were 
Tr-DNA positive but sputum liquid culture and Xpert MTB/RIF negative. 
Pa-
tient 
no 
HIV sta-
tus 
CD4 count 
(cells/mm
3
) 
Sex 
BMI 
(kg/m2) 
TB 
history 
Urine: Xpert MTB/RIF 
G007 Negative N/A Male 30.42 No Negative 
G009 Negative N/A Male 19.38 No Negative 
G086 Negative N/A Male 21.05 Yes Negative 
G120 Negative N/A Male 20.96 No Negative 
G129 Negative N/A Male 23.51 No Negative 
G136 Negative N/A Male 21.98 Yes Negative 
G138 Negative N/A Female 45.33 No Negative 
G140 Negative N/A Male 19.87 Yes Negative 
G142 Negative N/A Male 24.06 Yes Negative 
G179 Negative N/A Male 27.12 No Negative 
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Pa-
tient 
no 
HIV sta-
tus 
CD4 count 
(cells/mm
3
) 
Sex 
BMI 
(kg/m2) 
TB 
history 
Urine: Xpert MTB/RIF 
G047 Positive 206 Female 27.68 No Negative 
L082 Negative N/A Female 30.43 No Negative 
L115 Negative N/A Male 20.17 No Negative 
L134 Negative N/A Male 19.25 No Negative 
L152 Negative N/A Female 27.10 No Negative 
G031 Positive 483 Female 22.36 No Negative 
L030 Positive 505 Female 20.73 Yes Negative 
G052 Positive 513 Male 34.98 No Positive 
V006 Negative N/A Male 18.50 Yes Negative 
V020 Negative N/A Female 26.22 No Negative 
V022 Negative N/A Female 34.72 No Negative 
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5 Discussion  
This cross-sectional concept study demonstrates that the Tr-DNA assay detects pulmo-
nary TB independent of HIV status and level of immune suppression. Unlike the urine-
based TB LAM test, the performance of the Tr-DNA assay was independent of CD4 
values [84]. Furthermore, to our knowledge, this is the first study in which Mycobacte-
rium tuberculosis (MTB) is diagnosed using a target-specific direct repeat (DR) region. 
The DR region is present up to 42 times in the MTB genome; this can increase test 
sensitivity [80]. PCR analysis was performed in triplicates, and included appropriate 
controls to assure robustness and to avoid cross contamination. All controls worked 
within defined specifications. Iinternal process and negative controls were run with each 
DNA eluate tested; this allowed use to observed assay performance. Nevertheless, a 
moderate Tr-DNA assay sensitivity of 42.86% was observed, further indicates that not 
all patients with pulmonary TB will have free, circulating MTB-specific DNA passing 
through the kidneys into urine. The meta-analysis performed on eight Tr-DNA-based 
studies that used IS6110, rpoB and cfp/hf6 as targets for PCR analysis attained a slight-
ly higher sensitivity (55%) and specificity (94%) than the present study [62]. Further-
more, no correlation was found between the time to liquid culture positivity and Tr-DNA 
assay Ct value (r2 = 0.005). The rather low assay performance observed may have 
been due to several reasons, e.g., time of sample collection (spot vs morning) [62], 
storage duration of samples (up to three years) [70], and presence of PCR inhibitors in 
the urine and DNA eluate [85]. 
MTB-specific Tr-DNA fragments are even shorter; as small as 39 bp have been de-
scribed [86]. Therefore, we developed and optimised a capture matrix-based in-house 
nucleic acid method [87, 88] for the capturing of short Tr-DNA fragments (as small as 38 
bp). Many different sets of optimisation experiments were performed in comparison with 
Qiagen method. In addition we implemented in-house method on syringe pump to re-
duce hands-on time for isolation. A PCR target size of <150 bp has demonstrated Tr-
DNA sensitivities of 7 – 79% in alignment with the finding here of 42.86% [54, 65, 89]. 
Urine-based Tr-DNA molecular tests are useful for diagnosing pulmonary and extra-
pulmonary TB in underserved groups (children, HIV-positive and advanced 
immunosuppressed groups) [90]. However, few Tr-DNA-based studies have been 
performed with larger patient cohorts (n > 100); those that have showed sensitivities 
ranging from 15.7% [91] to 44% [92] for pulmonary TB. A lack of reliable nucleic acid 
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isolation and PCR methods may cause differences in reported sensitivity and specificity. 
Strong reproducibility of a Tr-DNA test is desired in order for it to be implemented in lim-
ited resource settings. However, Kafwabulula et al. (2002) repeated the Sechi and Aceti 
method for PCR analysis, and reported contradicting results [93] using an identical PCR 
method for DNA analysis; the only changes made were to the sample size and the Tr-
DNA isolation method. Furthermore, Amin et al. (2011) performed a study of extra-
pulmonary TB suspects and reported a sensitivity of 46.6% [89], and Moussa et al. 
(2000) reported a sensitivity and specificity of 96% and 98%, respectively, for genitouri-
nary TB [94].  
The total turn-around time (TAT) for the Tr-DNA assay was approximately 45 minutes, 
from Tr-DNA isolation to the fully-automated PCR process, including data analysis. This 
short TAT may allow a greater number of patients to be tested for TB, which may in turn 
further improve the disease control [95] The novel and rapid molecular assay targeting 
DR target was evaluated against the well-established IS6110 target on subset of study 
cohort. In preliminary comparison DR target showed high sensitivity and specificity 
compared to IS6110 target. Therefore, the whole study cohort urine was tested using 
DR region only. Once the complete cohort was tested using DR target, we observed the 
reduction in assay performance (sensitivity of 54% observed in preliminary study vs 
42.86% for complete cohort).  
The major findings of the current study are i) the in-house developed method described 
here can isolate nucleic acids from urine samples (as low as five copies of H37Rv 
gDNA), ii) the DSP-based amplification of the short DR target region in a single-use 
cartridge enables the detection and quantification of MTB-specific Tr-DNA in pulmonary 
TB, iii) assay performance is independent of HIV status and offers potential benefits to 
the standard of care when combined with sputum smear microscopy (providing a 
sensitivity of 83.82%). This study includes a detailed characterization of a large TB sus-
pect cohort, including demographic data, clinical symptoms and Tr-DNA characteriza-
tion in comparison to routine sputum-based diagnostic tests. The heterogeneity of the 
urine samples and the possible effect of this on assay performance was unavoidable 
due to the large sample size involved. 
The findings indicate that not all patients with a high bacterial load will excrete MTB into 
urine. Therefore, other, currently unknown, factors must influence DNA fragment excre-
tion. Although EDTA was added immediately after urine collection to assure DNA frag-
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ment stability, the limited sensitivity achieved here may have been associated with a 
minor degradation process, as the samples were not processed fresh [96]. Furthermore, 
the excess amount of EDTA added may also have inhibited the PCR process, which 
may in turn have resulted in reducing assay sensitivity [97]. In order to allow interpreta-
tion of the discordant results observed for extra-pulmonary and disseminated TB, partic-
ipant follow up would be required; this is missing from the current study. Furthermore, 
negative bacteriological tests results among discordant samples raises the question 
regarding which diagnostic method should be used as gold standard. Thus, the present 
study reveals a significant discrepancy between established methods of TB diagnosis 
and the Tr-DNA assay tested here. Therefore, this study serves as a preliminary inves-
tigation on which to base the future research and assay development. The effort to de-
velop a Tr-DNA-based molecular assay that runs on an automated analyser should fur-
ther be pursued to gain an understanding of the potential benefits it could bring to diag-
nostics. Likewise, the current in-house developed Tr-DNA isolation method requires 
technical skills to perform and to make it suitable to be used in limited resource settings; 
therefore, further simplification is required. This novel Tr-DNA diagnostic test should be 
evaluated for its impact on public health and its clinical utility to be used for diagnostics 
[98, 99]. A future Tr-DNA study should include the analysis of fresh urine samples, and 
participant inclusion criteria should not be limited to pulmonary TB only.  
6 Conclusion 
TB remains a major problem in developing the country and among HIV-infected pa-
tients. The TB diagnosis method is particularly valuable in a limited resource setting for 
timely initiation of therapy. Newer urine-based molecular methods could be an alterna-
tive to the current smear microscopy tests performed using sputum. This first proof-of-
concept, cross-sectional study demonstrates the possibility of diagnosing pulmonary TB 
using a novel Tr-DNA molecular assay implemented using a single-use cartridge, which 
is processed using an automated molecular analyser. Considering that MTB specific 
cell-free circulating DNA fragments present in the blood that pass through the kidney in 
urine. Furthermore, in-house developed method capable enough to extract the DNA 
fragments from larger urine volume. The overall sensitivity was moderate; however, a 
higher specificity was obtained. This in-house developed Tr-DNA isolation method also 
has the potential to be used for other body fluids, such as plasma. Although unsuitable 
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to be implemented as a stand-alone test, in combination with sputum smear microscopy, 
this Tr-DNA assay may have the potential to aid TB diagnosis in HIV-endemic regions, 
where sputum scarce and extra-pulmonary TB are common [100, 101].   
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8 Annex 
Appendix-1 Case Reporting Form 
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Appendix-2 Sequence information for the IS6110 target region present in 
the H37Rv Genome for possible primer binding and detection 
 
Sequence (36bp) 
5’-GACGCGATCGAGCAAGCCATCTGGACCCGCCAACAAGA-3’ 
Sense/Antisense From To 
Sense 3891708 3891745 
Antisense 3795446 3795483 
Sense 3711311 3711348 
Sense 3553642 3553679 
Sense 3552159 3552196 
Antisense 3120912 3120949 
Sense 2973038 2973075 
Antisense 2785003 2785040 
Sense 2636506 2636543 
Sense 2550943 2550980 
Antisense 2430505 2430542 
Sense 2366343 2366380 
Sense 1997030 1997067 
Antisense 1988091 1988128 
Antisense 1542340 1542377 
Sense 889950 889987 
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